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Angiotensin II is known to be the main effector peptide of the renin-angiotensin 
system (RAS) and acts on the angiotensin AT1 receptor to mediate the majority of 
its effects. New evidence is emerging that demonstrates the bioactivity of a variety 
of angiotensin II fragments, e.g., angiotensin III, angiotensin IV, des-Asp-
angiotensin I and angiotensin (1-7). This recent discovery has challenged our views 
on the final effectors and regulation of the RAS and the significance of poly 
angiotensins both physiologically and pathophysiologically. 
 
The aim of this project is to evaluate the role of angiotensin II and its immediate 
metabolites, angiotensin III, angiotensin IV, angiotensin (4-8) and angiotensin (3-7) 
on the regulation of pulmonary blood flow in the rabbit. We investigated the actions 
of these angiotensin peptides on isolated endothelium-denuded pulmonary trunk 
and artery tissue, and characterised the angiotensin receptor subtypes in vascular 
smooth muscle cells isolated from the rabbit pulmonary trunk and artery by receptor 
binding and Northern blot analysis. Finally, we evaluated the signal transduction 
pathways coupled to these receptors by measuring the production of inositol 
triphosphate, prostaglandin E2 and PGI2. Two major findings resulted from these 
experiments. We first provide evidence that the rabbit pulmonary vasculature is not 
just a passive conduit but may be an important regulator of blood flow from the 
heart to the lung. Secondly, we demonstrate the contribution of bioactive 
angiotensin fragments, e.g., angiotensin III and angiotensin IV, to the fine-
regulation of pulmonary vascular control. 
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 In the isolated tissue study, differential responses of the endothelium-denuded 
sections of the rabbit pulmonary trunk (the vessel arising from the right ventricle of 
the heart prior to its bifurcation into the left and right pulmonary arteries) and the 
two pulmonary arteries (vessels distal to the bifurcation) (see Figure 1.1) to 
angiotensin II and its immediate metabolites were observed. Angiotensin II further 
contracted noradrenaline pre-contracted sections of the pulmonary trunk and artery. 
In contrast, angiotensin III and angiotensin IV relaxed the pre-contracted sections of 
the pulmonary trunk while they were either inactive (angiotensin IV) or further 
contracted (angiotensin III) the pre-contracted sections of the pulmonary artery. The 
AT1 receptor mediated both the vasoconstrictor and vasodilator response since 
losartan, an AT1-selective receptor antagonist, blocked the vasoconstrictor and 
vasodilator response caused by all three angiotensin peptides and PD123319, an 
AT2-selective receptor antagonist, had no effect. Indomethacin, a cyclooxygenase 
inhibitor, blocked only the vasodilator response induced by angiotensin III and 
angiotensin IV in the trunk, indicating that vasodilator prostaglandins were 
probably involved in mediating this response. Amastatin, a selective 
aminopeptidase A and N inhibitor, blocked the angiotensin III-induced 
vasoconstrictor and vasodilator response in the pulmonary artery and trunk, 
respectively but did not significantly affect the angiotensin II and IV responses.  
 
This suggested that the angiotensin III-induced responses were mediated in part by 






Figure 1.1 The pulmonary trunk and artery 
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 breakdown product since angiotensin III is broken down by APN to generate 
angiotensin IV. Angiotensin (4-8) and angiotensin (3-7) were not bioactive in these 
preparations. 
 
Labelled Sar1-Ile8-angiotensin II bound with similar high affinity to pulmonary 
trunk (Kd = 0.959 ± 0.609 nM, Bmax = 0.34 ± 0.20 pmol/mg protein) and artery 
binding sites (Kd = 1.041 ± 0.330 nM, Bmax = 0.71 ± 0.19 pmol/mg protein) and was 
displaced by losartan with a Ki of 0.45 ± 0.74 nM and 31.1 ± 26.1 nM, respectively, 
but not by PD123319 and the AT4-selective antagonist, divalinal-angiotensin IV. 
These data were confirmed by a Northern blot analysis which revealed the presence 
of a single AT1 receptor subtype in both pulmonary trunk and artery VSMCs. 
 
The activation of PLC and PLA2 in response to angiotensin II, angiotensin III and 
angiotensin IV was evaluated by measuring inositol triphosphate production and 
prostaglandin E2 and PGI2 release, respectively. This is a first report comparing the 
angiotensin II-, angiotensin III- and angiotensin IV-induced prostaglandin and 
inositol triphospate signaling in tissues of the rabbit pulmonary vasculature. 
 
Angiotensin II significantly increased the production of both prostaglandin E2 and 
PGI2 in the rabbit pulmonary trunk and artery VSMCs. This increase was inhibited 
by losartan but not by PD123319, implicating the role of AT1 receptors in 
mediating this response. The stimulation of pulmonary trunk and artery VSMCs by 
angiotensin III and angiotensin IV was associated with an increase in both 
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vasodilator prostaglandins and a reduction of this release by losartan and 
indomethacin. The magnitude of prostaglandin release did not differ significantly 
between the trunk and artery cells for all three angiotensin peptides tested. 
Following this finding, we demonstrated that angiotensin II stimulates a higher 
production of IP3 in pulmonary trunk tissue slices compared to that by angiotensin 
IV, suggesting that the differential angiotensin II-induced vasoconstrictor response 
and angiotensin IV-induced vasorelaxant response in the rabbit pulmonary trunk 
may be due to higher amounts of the inositol triphosphate second messenger being 
produced when stimulated by angiotensin II compared to angiotensin IV.  
 
Taken together, the present findings indicate that the response seen in the 
pulmonary vasculature is likely a result of a balance of contractile, i.e., inositol 
triphosphate production, and relaxant, i.e., prostaglandin release, signaling 
components. It also supported the notion that a single AT1 receptor is involved, and 
it is possible that this receptor is coupled to a single or multiple G proteins which, 
when activated, triggers the activation of multiple signaling pathways that 
contribute to the final vascular response. Moreover, the vasorelaxant action of 
angiotensin IV, which is formed when angiotensin II is metabolized, may contribute 
to the modulation of contractile actions mediated by angiotensin II in the pulmonary 
trunk. Importantly, this fine-regulation of angiotensin responses in the pulmonary 
trunk, which receives blood directly from the right ventricle, may play a role in the 
protection of the delicate pulmonary capillaries from excessive systolic pressure. 
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Understanding these protective mechanisms may have important therapeutic 






The renin angiotensin system (RAS) plays an important role in the regulation of 
blood pressure, plasma volume, sympathetic nervous activity and thirst responses. 
Its remarkable diversity of physiologic actions include vasoconstriction in vascular 
smooth muscle, cardiac contractility and heart rate through its actions on the 
sympathetic nervous system, alteration of renal sodium and water absorption by 
acting directly on renal vasculature and through its ability to stimulate the zona 
glomerulosa cells of the adrenal cortex to synthesize and secrete aldosterone, thirst 
enhancement in the brain and secretion of the antidiuretic hormone from the 
pituitary gland. What is striking about the RAS is that despite its wide range of 
actions on many different target organs in the body, angiotensin II is known to be 
its main effector peptide and the AT1 receptor is established as the principle site of 
the biological action of angiotensin II.   
 
In contrast to other G-protein coupled receptor systems, such as the adrenoceptors, 
muscarinic receptors, serotonin receptors and dopamine receptors, where subtypes 
mediate a wide array of biological responses, it seemed an exception rather than the 
norm that only one effector peptide (i.e. angiotensin II) and one receptor subtype 
(i.e., AT1) mediate the majority of the effects of the RAS. It was only in the late 
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1980s that the existence of a second angiotensin receptor subtype, the AT2, was 
demonstrated with the development of receptor specific antagonists, e.g. losartan 
and PD 123319. However, this did little to account for the myriad of angiotensin 
responses since the AT1 receptor mediates virtually all of the known physiological 
actions of angiotensin II in target cells.  
 
It is therefore of interest to note that new evidence is emerging that demonstrates, in 
addition to angiotensin II and III, bioactivity of a variety of angiotensin fragments, 
e.g. des-Asp-angiotensin I (Sim and Soh, 1995; Sim  and Chai, 1996; Sim and Min, 
1998; Min et al., 2000), angiotensin IV (Wright et al., 1995) and angiotensin (1-7) 
(Ferrario et al., 1998). In addition, putative binding sites for angiotensin IV (AT4) 
and angiotensin (1-7) have been demonstrated and pharmacologically characterized 
(Swanson et al., 1992; Hall et al., 1993; Hanesworth et al., 1993; Nuess et al., 1994; 
Wright et al., 1994; Bernier et al., 1995), although their cloning has not been 
reported. These recent findings have challenged the ‘single’ regulatory peptide and 
receptor concept of the RAS and opened up the possibilities of poly functional 
angiotensins in the system.  
 
The present literature review focuses on the formation of bioactive angiotensin 
fragments from angiotensin I and angiotensin II, the angiotensin receptor types and 
their distribution, vascular AT1 receptor signaling mechanisms, and finally evidence 
for multiple signal transducers coupled to the angiotensin AT1 receptor subtype. 
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1.2 The Renin Angiotensin System (RAS) - Production of Angiotensin II 
and Other Bioactive Angiotensin Peptides 
1.2.1 Systemic and Tissue RAS 
Angiotensin II is produced systemically via the classical RAS, and locally via tissue 
RAS. In the classical RAS, circulating renal-derived renin cleaves hepatic-derived 
angiotensinogen to form angiotensin I, which is converted to angiotensin II by 
angiotensin converting enzyme in the lungs. The existence of a local tissue RAS is 
evidenced by the localization of many of its components in tissues. All components 
of the RAS, except renin, have been demonstrated to be produced in the 
vasculature. The locally produced angiotensin II exerts paracrine and autocrine 
effects in the vicinity of its site of formation. 
 
1.2.2 Bioactive angiotensin fragments 
Angiotensin II is metabolized into active angiotensin peptides by enzymes acting at 
the two ends of the peptide (Figure 1.2). Its precursor, angiotensin I, can be 
similarly degraded. Four angiotensin fragments are of biological interest: 
angiotensin III, which is obtained by deletion of the N-terminal aspartic acid from 
angiotensin II; angiotensin IV, which is obtained by deletion of the N-terminal 
arginine from angiotensin III; angiotensin (1-7), which is obtained by deletion of   
the  C-terminal   phenylalanine   from angiotensin  II; and des-Asp- angiotensin I, 
which is obtained by deletion of the N-terminal aspartic acid from angiotensin I (see 
Figure 1.2).   
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NH2-Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10-Val11-Ile12-His13-Asn14-COOH 
            (Angiotensinogen)          
         renin              
          NH2-Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-His9-Leu10-COOH   
                          (Angiotensin I)  
                             prolyl/neutral        ACE 
                           endopeptidases                     chymase (in heart)              aminopeptidase X 
                           aminopeptidase A 
                NH2-Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-COOH   
               (Angiotensin II)               
        NH2-Arg2-Val3-Tyr4-Ile5-His6-                        
                     Pro7-Phe8-His9-Leu10-COOH   
                                                                       (des-Asp-angiotensin I) 
NH2-Asp1-Arg2-Val3-Tyr4         
-Ile5-His6-Pro7-COOH        aminopeptidase A  
(Angiotensin (1-7))          ACE 
          
     
            NH2-Arg2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-COOH 
    Inactive            (Angiotensin III) 
    fragments (?)                          aminopeptidase N   
    
              NH2-Val3-Tyr4-Ile5-His6-Pro7-Phe8-COOH 
             (Angiotensin IV) 
            aminopeptidase N (?) 
            dipeptidylaminopeptidase (?) 





other active/inactive fragments (?) 
 
Figure 1.2 Metabolism of angiotensinogen 
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 1.2.3 Angiotensin III 
Angiotensin II is converted to angiotensin III by aminopeptidase A (APA) that 
selectively cleaves the aspartyl residue of angiotensin II (Reaux et al., 1999b). 
Angiotensin III is generally less potent in peripheral target tissues than angiotensin 
II because it is rapidly degraded due to the large distribution of aminopeptidase N 
(APN), which metabolizes angiotensin III, but not angiotensin II, to angiotensin IV 
(Gaynes et al., 1978; Ahmad and Ward, 1990). However, angiotensin III was 
recently demonstrated to be the main effector peptide in the central regulation of 
blood pressure (Reaux et al., 1999a; Reaux et al., 2001), and in the hypothalamus in 
the stimulation of antidiuretic hormone secretion (Zini et al., 1996). The studies 
were carried out with the recently developed specific APA and APN inhibitors, 
EC33 and PC18, respectively (Fournie-Zaluski et al., 1992; Chauvel et al., 1994; 
Reaux et al., 1999a). These new agents represent invaluable new tools to ascribe a 
physiological effect to a given angiotensin II fragment. For example, an effect 
inhibited by EC33 and potentiated by PC18 can be attributed to angiotensin III. 
Similarly, an effect inhibited by PC18 can be attributed to angiotensin IV. Central 
inhibition of APA by EC33 not only blocked the pressor action of angiotensin II but 
also caused a fall in basal blood pressure comparable to that caused by i.c.v. 
administration of losartan, indicating a requirement for angiotensin III in the tonic 
regulation of blood pressure. Furthermore, the inhibition of APN activity 
(responsible for converting angiotensin III to angiotensin IV) by PC18 caused an 
increase in blood pressure that was blocked by losartan. This suggests that 
inhibition of angiotensin III degradation by PC18 causes an increase in angiotensin 
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III levels that elevates blood pressure through an action on AT1 receptors. These 
observations indicate the potential applications of APA inhibitors as centrally acting 
compounds in the management of hypertension (Reaux et al., 1999b, Reaux et al., 
2000).  
 
1.2.4 Angiotensin IV 
Angiotensin IV, formed from the action of APN on angiotensin III (Kugler, 1982; 
Palmieri et al., 1989), appears to exhibit both the same properties as angiotensin II 
via activation of AT1 receptors as a weak agonist, and specific properties via its 
own putative receptors. Gardiner et al. (1993) noted that angiotensin IV-induced 
reductions in renal and mesenteric blood flows and vascular conductances in 
conscious rats were blocked by losartan. In agreement with these findings, 
Fitzgerald et al. (1999) noted angiotensin IV-induced reductions in renal artery 
blood flow, which were blocked by losartan, suggesting mediation by AT1 
receptors. Champion et al. (1998, 1999) also reported that candesartan decreased 
pressor responses to angiotensin IV in the anesthetized rat and the cat mesenteric 
vascular bed with a shift to the right of the dose-response curve. Similarly, 
angiotensin IV, although less potent than angiotensin II and angiotensin III, 
produced a pressor response after i.c.v. injection, which was inhibited by losartan 
(Wright et al., 1996). 
 
In contrast, Kramar et al. (1997) and Coleman et al. (1998) reported that 
angiotensin IV-induced elevation of cerebral and renal cortical blood flow was 
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blocked by a specific antagonist divalinal-angiotensin IV, and not by losartan or 
PD123319. In a related study, Kramer et al. (1998) noted that pretreatment with the 
NO synthase inhibitor, Nω-nitro-L-arginine (L-NAME) blocked the vasodilatory 
effect of angiotensin IV on rat cerebral vasculature, suggesting that the latter action 
is dependent upon the synthesis and release of NO from vascular endothelial cells. 
Coleman et al. (1998) obtained similar results concerning kidney cortical blood 
flow. Recently, Hill-Kapturczak et al. (1999) and Patel et al. (1998) suggested that 
angiotensin IV mediated the angiotensin II-induced NO release and increase in 
constitutive nitric oxide synthase (cNOS) activity, respectively, via the AT4 
receptor in porcine pulmonary arterial endothelial cells since divalinal-angiotensin 
IV blocked both angiotensin II- and angiotensin IV-induced NO release and 
increases in cNOS activity while AT1 and AT2 blockade failed to influence these 
responses. Interestingly, AT1 and AT4 receptors often mediate opposite effects. 
 
Angiotensin IV has also been reported to block angiotensin II-induced RNA and 
protein synthesis in chick cardiocytes (Baker et al., 1990, 1992), suggesting a 
potential role for the angiotensin IV system in cardiac hypertrophy. Brazsko and 
collegues (1988, 1991) established that i.c.v. injected angiotensin II and angiotensin 
IV were equivalent at facilitating exploratory behaviour in rats tested in an open 
field, and improved recall of passive avoidance conditioning and acquisition of 
active avoidance conditioning. Divalinal-angiotensin IV disrupted recall of this 
response (Wright et al., 1995), implicating the angiotensin IV system in memory 
acquisition and recall. The binding site for angiotensin IV has recently been 
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identified as insulin-regulated aminopeptidase (IRAP), a transmembrane enzyme, 
based on the fact that the two proteins share several pharmacological and 
biochemical properties (Caron et al., 2003). This binding site also binds the 
endogenous ligand, LVV-hemorphin-7, with high affinity and elicits similar 
physiological effects as activation by the angiotensin IV ligand (Lee et al., 2003). 
The identification of additional functions awaits further elucidation of this new 
receptor system. 
 
The degradation pathways of angiotensin IV are not yet fully elucidated but APN, 
dipeptidylaminopeptidase (DAP) and carboxypeptidase N (CPN) have been 
implicated in its N- and C-terminal degradation (De Silva et al., 1988; Welches et 
al., 1991; Chansel et al., 1998). The possible degradation products of angiotensin IV 
include the N-terminal-deleted angiotensin (4-8) and angiotensin (5-8), and the C-
terminal-deleted angiotensin (3-7) (Figure 1.2). 
 
1.2.5 Angiotensin (1-7) 
Angiotensin I can be processed into angiotensin (1-7) by prolylendopeptidase 
(Welches et al., 1991) and three tissue endopeptidases, neutral endopeptidase (NEP) 
24.11, NEP 24.15 and NEP 24.26 (Yamamoto et al., 1992; Ferrario et al., 1997). 
Angiotensin (1-7) can also be derived from angiotensin II by the action of 
prolylendopeptidase or carboxypeptidases. Once formed, angiotensin (1-7) can be 
metabolized by aminopeptidases to generate angiotensin (2-7) and angiotensin (3-
7). ACE hydrolysis of angiotensin (1-7) to generate angiotensin (1-5) is recently 
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demonstrated to be an important route for inactivation of circulating and, possibly, 
tissue angiotensin (1-7) (Yamada et al., 1998; Chappell et al., 2000). 
 
The same receptor duality has been demonstrated for angiotensin (1-7). This 
peptide exhibits several effects that are blocked by AT1 antagonists, including the 
release of 3H-noradrenaline from rat atria (Gironacci et al., 1994) and the increase 
in fluid absorption in the proximal tubule (Garcia et al., 1994) and in Henle’s loop 
(Vallon et al., 1997). In addition to the AT1 receptors, angiotensin (1-7) recognizes 
its own receptors, which have been described in a number of preparations (Diz and 
Ferrario, 1996; Tallant et al., 1997).  
 
Although a specific receptor for angiotensin (1-7) has yet to be cloned, there are a 
number of evidence for its existence that are based on (i) opposing and/or 
differential actions of angiotensin (1-7) when compared to angiotensin II, which 
includes facilitation of baroreflex sensitivity (Benter et al., 1995; Oliveira et al., 
1996), absence of dipsogenic (Mahon et al., 1995) and pressor effect (Campagnole-
Santos et al., 1992) after i.c.v. injection, vasodilation (Benter et al., 1995), anti-
proliferative (Freeman et al., 1996) and anti-angiogenic actions (Machodo et al., 
2000) and increase in diuresis and natriuresis (Handa et al., 1996); (ii) the 
characterization of a selective angiotensin (1-7) antagonist, D-Ala7-angiotensin (1-
7), which antagonized central and peripheral actions of angiotensin (1-7) (Ambuhl 
et al., 1994; Bomtempo et al., 1998; Vallon et al., 1998; Widdop et al., 1999); and 
(iii) the non-interference of D-Ala7-angiotensin (1-7) with the pressor, myotropic or 
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dipsogenic effect of angiotensin II or binding of 125I-angiotensin II to cortical or 
medullary adrenal membranes that are rich in AT1 and AT2 receptors, respectively 
(Santos et al., 1994).  
 
1.2.6 des-Asp-angiotensin I 
The formation of angiotensin III from angiotensin I via des-Asp-angiotensin I was 
first described by Blair-West et al. (1971). In this pathway, angiotensin I undergoes 
enzymatic NH2-terminal degradation to form des-Asp-angiotensin I, bypassing 
ACE action to form angiotensin II. Des-Asp-angiotensin I is subsequently 
metabolized by ACE to angiotensin III. Homogenates of endothelium, vascular 
smooth muscle and hypothalamus was found to convert exogenous angiotensin I to 
des-Asp-angiotensin I instead of angiotensin II (Sim MK, 1993; Sim and Qiu, 1994; 
Sim et al., 1994a). The enzyme responsible for this conversion was found to be a 
novel specific aminopeptidase (named aminopeptidase X) that is not inhibited by 
EDTA, bestatin or amastatin (Sim et al., 1994).  The existence of this specific 
pathway and functional studies on des-Asp-angiotensin I seem to indicate that des-
Asp-angiotensin I is a likely functional angiotensin peptide of the RAS. 
 
The significant increase in activity of aminopeptidase X in the hypothalamus of the 
SHR suggests that in this hypertensive animal, the degradation of angiotensin I to 
angiotensin II is shunted in favour of des-Asp-angiotensin I (Sim and Lim, 1997), 
indicating that des-Asp-angiotensin I is possibly associated with blood pressure 
regulation and hypertension. This role is supported by the ability of des-Asp-
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angiotensin I to attenuate dose-dependently the central pressor actions of 
angiotensin II and angiotensin III in both SHR and normotensive WKY rats (Sim 
and Radhakrishnan, 1994). 
 
In the heart, orally or intravenously administered des-Asp-angiotensin I attenuated 
the development of experimentally-induced cardiac hypertrophy which was 
comparable to the attenuation produced by losartan; the des-Asp-angiotensin I-
induced attenuation was blocked by indomethacin (Sim and Min, 1998). Isolated 
tissue studies demonstrated that des-Asp-angiotensin I relaxed pre-contracted rabbit 
pulmonary trunk strips but further contracted pre-contracted pulmonary artery 
strips. Both des-Asp-angiotensin I-induced opposing actions were inhibited by 
losartan, but not by PD123319; only the des-Asp-angiotensin I-induced relaxation 
was inhibited by indomethacin (Sim and Chai, 1996). Binding studies also revealed 
that the angiotensin receptor exists in two guanine nucleotide-differentiated 
subtypes in the same pulmonary trunk and artery (Sim and Lim, 1998).  
 
In the RAS, it is apparent that angiotensin peptides may bind to multiple receptor 
subtypes that often exhibit different, and sometimes opposing, actions. For 
example, angiotensin II has been shown to bind to both AT1 and AT2 receptors, 
which are coupled to different effector systems and elicit different biological 
responses. In addition, the signaling from the RAS appears to have an additional 
level of complexity arising from extracellular processing of the ligand, the 
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metabolites of which bind the same or different receptors and induce additional 
effects.  
 
1.3 Angiotensin Receptors  
Angiotensin II mediates its effects via at least two cell surface receptors, AT1 and 
AT2. Both subtypes have been cloned and pharmacologically characterized and 
belong to the G-protein coupled receptor (GPCR) superfamily. Pharmacologically 
the receptors can be distinguished according to inhibition by specific antagonists, 
e.g., biphenylimidazoles such as losartan for AT1 receptors and 
tetrahydroimidazopyridines such as PD123319 for AT2 receptors (de Gasparo et al., 
1995; Ardaillou, 1999). Two other receptors (AT3 and AT4) have recently been 
proposed but their transduction mechanisms are unknown and they have not yet 
been cloned.  
 
1.3.1 Distribution in vasculature 
AT1 receptors are predominant in the control of angiotensin II-induced vascular 
functions (Sadoshima, 1998; de Gasparo et al., 2000). In the vasculature, AT1 
receptors are present at high levels in smooth muscle cells and relatively low levels 
in the adventitia and are undetectable in the endothelium (Zhuo et al., 1998; Allen 
et al., 2000). Conversely, AT2 receptors predominate in the adventitia and are 
detectable in the media (Zhuo et al., 1998). 
 
 18
1.3.2 AT1 receptor 
Two AT1 receptor subtypes that are encoded by different genes have been described 
in rodents. The AT1A (which is the predominant subtype in all tissues except 
adrenal and pituitary glands) and the AT1B (predominant subtype in adrenal and 
pituitary glands) have greater than 95% amino acid sequence identity (Iwai and 
Inagami, 1992). AT1A and AT1B receptors exhibit similar ligand binding and signal 
transduction properties but differ in their tissue distribution and transcriptional 
regulation.  
 
The human AT1 receptor contains 359 amino acids and is encoded by a single gene. 
The existence of a second AT1 gene in humans was suggested by the isolation of a 
human cDNA clone that differed from the known sequence in 10 of its 359 residues 
(Konishi et al., 1994; Kuroda et al., 1994) and by Southern blot analysis (Mauzy et 
al., 1992). However, Southern blot (Curnow et al., 1992; Yoshida et al., 1992; 
Bergsma et al., 1992; Aiyar et al., 1994; Su et al., 1996) and single stranded 
conformational polymorphism analyses (Bonnardeaux et al., 1994) performed by 
other laboratories do not support the presence of a second gene in humans. In 
addition, the analysis of the evolution of AT1 gene in the mouse, rat, bovine and 
human was consistent with rodents possessing two similar but separate genes, and 
with bovine and human having only a single class gene (Yoshida et al., 1992). 
Hence, it was suggested that the novel human AT1 cDNA clone obtained by 
Konishi and collegues probably corresponded to an unusual allelic form of the AT1 
gene that is not generally present in the human population (Curnow KM, 1996). In 
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the rabbit, Southern analysis of genomic DNA similarly revealed a single gene 
encoding the AT1 receptor (Burns et al., 1993; Aiyar et al., 1994). 
 
The human AT1 gene contains five exons that produce mature RNAs that encode 
two receptor isoforms as a result of alternative splicing (Curnow KM, 1996). Exon 
5 contains the open reading frame for AT1 (referred to as the short isoform) while 
transcripts containing exon 3 spliced to exon 5 (exons 3/5) encode a receptor with 
an amino terminal extension of 32 amino acids (long isoform). The relative 
abundance of the mRNA splice variants encoding the long and short isoforms varies 
widely in human tissues, suggesting that the isoforms may be functionally distinct 
(Martin et al., 2001). In a similar study, Martin and colleagues (2001) also 
demonstrated that the exons 3/5 splice variant encodes the long isoform in vivo and 
that it has a diminished affinity for angiotensin II (> 3-fold) when compared to the 
short isoform. This reduced affinity corresponded to a shift to the right in the does-
response curve for angiotensin II-induced IP3 production and Ca2+ mobilization. 
Interestingly, losartan cannot discriminate between the two human AT1 receptor 
isoforms. However, the physiological and pathophysiological roles of the long and 
short AT1 receptors remain to be investigated.  
 
Structural variation produced by alternative splicing observed in many GPCRs has 
resulted in differences in signal transduction. For example, Pantaloni et al. (1996) 
reported a splice variant of the pituitary adenylate cyclase-activating polypeptide 
(PACAP) receptor, characterized by a 21-amino-acid deletion in the N-terminal 
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extracellular domain, which resulted in the increased potency of PACAP-27 in PLC 
stimulation. The existence of this splice variant is suggested to be a possible way to 
fine-tune PLC stimulation by PACAP. Differences in G protein coupling affinities, 
and consequently different modes of signal transduction, have also been 
demonstrated in two alternatively-spliced isoforms of the dopamine D2 receptor 
which differ by a 29-amino-acid insertion in the putative third intracellular loop of 
the receptor (Picetti et al., 1997). Similarly, Pierce et al. (1998) demonstrated that 
splice variants of the prostanoid EP1, EP3, FP and TP receptors differed not only in 
their second messenger pathways but also in their levels of constitutive activity and 
their desensitization.  
 
1.3.3 AT2 receptor 
The human and rodent AT2 receptors contain 363 amino acids with 99% sequence 
identity between rat and mouse and 72% identity between rat and human (Ichiki et 
al., 1994; Tsuzuki et al., 1994). The divergence between rodent and human AT2 
occurs mainly in the N-terminal region. AT1 and AT2 receptors have only 33 to 
24% amino acid sequence identity (Kambayashi et al., 1993; Nakajima et al., 1993). 
The residues in the transmembrane hydrophobic domains of the receptor which are 
considered to be important for angiotensin II binding tended to be preserved, while 
extensive differences between the AT1 and AT2 receptors are seen in the third 
intracellular loop and the carboxyl terminal tail.  
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AT2 receptor expression is ubiquitous in the fetus but declines precipitously after 
birth in many but not all tissues (de Gasparo et al., 2000). For example, it decreases 
to undetectable levels in the skin after birth but in the adrenal and heart, the decline 
stops at certain levels, and AT2 receptor expression persists for life (de Gasparo et 
al., 2000). However, AT2 receptor expression can be up-regulated after tissue 
injury, e.g., during wound healing of the skin (Kimura et al., 1992; Viswanathan 
and Saavedra, 1992) and post balloon catheterization of rat carotid artery (Janiak et 
al., 1992; Viswanathan et al., 1994). It is therefore postulated to play the role of a 
modulator of biological programs in tissue development and repair. 
 
Recent evidence also suggests that the AT2 receptor may have a physiological role 
in the regulation of blood pressure, and may antagonize AT1-mediated effects by 
inhibiting cell growth and by inducing apoptosis and vasodilation (Horiuchi et al., 
1997; Touyz et al., 1999b). Other novel, physiological effects attributed to the AT2 
receptor include modulation of thirst, behaviour, and locomotor activity (Hein et al., 
1995; Ichiki et al., 1995). 
 
1.3.4 AT3 receptor 
A binding site observed in the Neuro-2a mouse neuroblastoma cell line that was not 
blocked by losartan or PD123319, not affected by GTP analogs and has a low 
affinity for angiotensin III, was assigned the AT3 receptor (Chaki and Inagami, 
1992). It may however be more appropriate to classify it as a non-AT1-non AT2 site 
until more information about its nature has been obtained. 
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 1.3.5 AT4 receptor  
The AT4 receptor binds angiotensin IV and specific antagonist divalinal-angiotensin 
IV, but not losartan or PD 123319, and is prominently expressed in brain structures 
concerned with cognitive processing, motor and sensory functions (Wright et al., 
1995). Peripheral tissues that reveal heavy distributions of AT4 sites are the kidney, 
bladder, heart, spleen, prostate, adrenals and colon (de Gasparo et al., 2000). The 
physiological functions so far associated with the AT4 receptor include memory 
acquisition and recall, regulation of blood flow, inhibition of renal tubular 
reabsorption, and cardiac hypertrophy (Braszko et al., 1988, 1991; Baker et al., 
1990, 1992; Kramer et al., 1997; Coleman et al., 1998; Handa et al., 1998).  
 
1.4 AT1 Signaling Pathways in the Vasculature 
Angiotensin II elicits complex and highly regulated cascades of intracellular signal 
transduction that lead to short term vascular effects, such as contraction, and to 
long-term biological effects, such as cell growth, migration, extracellular matrix 
deposition, and inflammation (Touyz et al., 2000). The signal transducers 
associated with the AT1 receptor include adenylate cyclase and phospholipases C, D 
and A2 (PLC, PLD and PLA2) (Figure 1.3). The signaling processes are multiphasic 
with distinct temporal characteristics. Immediate, early and late signaling events 
occur within seconds, minutes, and hours, respectively. 
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  Figure 1.3 Angiotensin AT1 receptor-mediated signaling pathways in 
vascular smooth muscle cells. Binding of angiotensin II to the AT1 
receptor stimulates the activation of phospholipase C (PLC), 
phospholipase D (PLD) and phospholipase A2 (PLA2). PLC activation 
leads to phosphatidylinositol-4,5-biphosphate (PIP2) hydrolysis and the 
formation of inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 
releases Ca2+ (Ca) from sarcoplasmic reticular stores, and DAG activates 
protein kinase C (PKC), which in turn activates the Na+/H+ exchanger 
(Na+-H+). This latter event leads to intracellular alkalinization and 
together with the increase in intracellular Ca results in vascular smooth 
muscle contraction. Ca influx is also stimulated. PLD activation results in 
the hydrolysis of phosphatidylcholine (PC) to phosphatidic acid (PA), 
which can be converted to DAG by phosphatidic acid phosphorylase (PP). 
PLA2 activation results in the production of arachidonic acid which is 
processed into eicosanoids. These eicosanoids attenuate angiotensin 
responses by enhancing or attenuating angiotensin-induced 
vasoconstriction. 
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Vascular AT1-mediated signaling mechanisms that occur within seconds of ligand 
binding include (a) G protein-mediated PLC activation, and subsequent formation 
of inositol triphosphate (IP3) and diacylglycerol (DAG), (b) increase in intracellular 
free calcium concentration by mobilizing intracellular Ca2+ and increasing Ca2+ 
influx, (c) activation of protein kinase C (PKC), (d) intracellular alkalinization via 
stimulation of Na+/H+ exchanger, (e) increase in intracellular free sodium 
concentration and decrease intracellular free magnesium concentration, and (f) 
activation of Src family of kinases. 
 
In addition to rapid signaling events, the vascular AT1 receptor also mediates early 
signaling events that include (a) phospholipase A2 (PLA2) activation and 
arachidonic acid metabolism, (b) phospholipase D (PLD) activation, (c) modulation 
of cyclic nucleotides via adenylate and guanylate cyclases, (d) tyrosine kinase 
phosphorylation (activation), and (e) mitogen-activated protein kinase (MAPK) 
activation. 
 
1.4.1 Stimulation of phospholipase C and inositol phosphate signaling 
Activation of the AT1 receptor results in a rapid, PLC-dependent hydrolysis of 
phosphatidylinositol-4,5-biphosphate (PIP2) to yield water soluble IP3 and 
membrane bound DAG (Griendling et al., 1989) (Figure 1.3). There are at least 
three isoforms of PLC: PLC-β, PLC-γ and PLC-δ (Rhee and Choi, 1992). PLC-β 
isoforms are regulated by Gq/11 proteins (Smrcka et al., 1991), whereas PLC-γ 
isoforms are regulated by tyrosine phosphorylation (Marrero et al., 1994). PLC-δ 
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regulation is unclear, but may involve intracellular Ca2+. All three isoforms have 
been identified in vascular smooth muscle cells (VSMCs) (Schelling et al., 1991; 
Ushio-Fukai et al., 1998). PLC-β appears to be important in the rapid generation of 
IP3 (within 15 s), whereas PLC-γ seems to play a role in the later phase of IP3 
formation (Ushio-Fukai et al., 1998). IP3 stimulates release of Ca2+ from 
sarcoplasmic/endoplasmic reticular stores (which constitute the initial Ca2+ transient 
phase) and DAG, with cofactors phosphatidylserine and Ca2+, activates PKC.  
 
1.4.2 Increase in intracellular calcium 
Exact mechanisms whereby AT1 activation stimulates subsequent Ca2+ influx (the 
second Ca2+ phase) are unclear and may involve voltage-dependent calcium 
channels, Ca2+-permeable and nonspecific dihydropyridine-sensitive cation 
channels, receptor-gated Ca2+ channels, Ca2+-activated Ca2+ release channels, and 
activation of the Na+/Ca2+ exchanger (Arnaudeau et al. 1996; Lu et al., 1996). 
Transmembrane Ca2+ influx appears to contribute to the sustained AT1-induced 
vasoconstriction (Ruan and Arendshorst, 1996b). 
 
1.4.3 Regulation of smooth muscle contraction and relaxation 
Smooth muscle contraction is regulated by the intracellular Ca2+ concentration and 
by the Ca2+ sensitivity of the regulatory light chains of myosin (MLC20) (Somlyo et 
al., 1994). The Ca2+ sensitivity of MLC20 is determined by the phosphorylation and 
dephosphorylation of MLC20 catalyzed by Ca-calmodulin-activated myosin light-
chain kinase (MLCK) and myosin light-chain phosphatase (MLCP), respectively. 
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The amplitude of force generation thus depends on the balance of activities of 
MLCK and MLCP. MLCK and MLCP are therefore targets for intracellular 
signaling cascades, whose activities can be modulated independent of changes in 
Ca2+. Smooth muscle tone appears to depend on a network of activating and 
inhibiting intracellular signals integrating incoming extracellular signals where Ca2+ 
is just one, albeit important, player. 
 
The angiotensin II-induced increase in intracellular Ca2+ results in the binding of 
Ca2+ to calmodulin. Association of the Ca2+-calmodulin complex with the catalytic 
subunit of MLCK activates this enzyme. MLCK then phosphorylates serine at 
position 19 on MLC20, allowing the myosin ATPase to be activated by actin and the 
muscle to contract. Conversely, a decrease in intracellular Ca2+ causes inactivation 
of MLCK, thus permitting the dephosphorylation of MLC20 by MLCP and 
subsequent deactivation of the actomyosin ATPase, resulting in relaxation (Somlyo 
et al., 1994; Pfitzer G, 2001) (Figure 1.4). 
 
In addition, recent evidence has demonstrated that angiotensin II can increase the 
Ca2+ sensitivity of MLC20 by modifying, independently of Ca2+, the activity of the 
MLCP (Seko et al., 2003). The major mechanism of G-protein coupled Ca2+ 
sensitization is the inhibition of MLCP, resulting in an increase in MLC20 
phosphorylation, and hence contractile force, at a given intracellular Ca2+ 
concentration (Kitazawa et al., 1991). The inhibition of MLCP is mediated 
primarily by a PKC- and Rho-kinase- (RhoA-activated kinase) dependent  
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Figure 1.4 Regulation of smooth muscle contraction and relaxation. 
Angiotensin II-induced increase in intracellular Ca results in binding of Ca to 
calmodulin. Association of the Ca-calmodulin complex with myosin light 
chain kinase (MLCK) causes MLCK activation and the subsequent 
phosphorylation of the regulatory light chains of myosin. This activates 
myosin ATPase resulting in contraction. A decrease in intracellular Ca results 
in inactivation of MLCK and this permits myosin light chain phosphatase 
(MLCP) to dephosphorylate myosin, resulting in deactivation of myosin 
ATPase and relaxation. 
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phosphorylation of CPI-17, an endogenous protein inhibitor of MLCP, at Thr-38, 
via Gq/G11 and G12/G13 proteins (Kitazawa et al., 1991; Gohla et al., 2000; Niiro et 
al., 2003; Seko et al., 2003) (Figure 1.5). It has been suggested that atypical PKCs 
act upstream of Rho-kinase and are involved in the activation pathway of Rho 
kinase although its mechanism is unclear (Gailly et al., 1997; Niiro et al., 2003). 
Rho kinase is one of the major downstream targets of the monomeric GTPase 
RhoA; RhoA is activated upon the exchange of bound GDP for GTP and its activity 
is regulated by GTPase activating proteins (GAPs) and guanosine exchange factors 
(GEFs) (Laufs and Liao, 2000; Somlyo and Somlyo, 2000). Angiotensin II was 
demonstrated to cause RhoA activation in rat VSMCs and rabbit clitoral 
cavernosum smooth muscle (Park et al., 2002; Seko et al., 2003) but not in isolated 
rabbit aortic tissue (Sakurada et al., 2001). The role of RhoA in mediating the 
signaling mechanism of angiotensin II-mediated vasoconstriction remains to be 
determined. Other proposed mechanisms of MLCP inhibition include Rho-kinase-
induced phosphorylation of the myosin binding unit (MBS) of MLCP at Thr-641 
and dissociation of MLCP by arachidonic acid (Gong et al., 1995; Hartshorne et al., 
1998).
 
1.4.4 Activation of protein kinase C and intracellular alkalinization 
AT1 activation also stimulates the translocation of cytosolic PKC to the plasma 
membrane where the activated enzyme phosphorylates specific proteins associated 































Figure 1.5 Modulation of the Ca sensitivity of myosin by modifying 
the activities of MLCK and MLCP.  MLCP can be inhibited by 
phosphorylated CPI-17 via a PKC- and Rho-kinase-dependent 
pathway. Arachidonic acid inhibits MCLP activity by dissociation of 
MLCP. Rho-kinase is the downstream effector of RhoA, which is 
activated by guanosine exchange factors (GEF) and inactivated by 
GTPase-activating proteins (GAP). 
 30
 receptors, tyrosine kinase, cytochrome P450, HMG-CoA reductase (Walsh et al., 
1996; Damron et al., 1998). PKC is implicated in AT1-induced vascular contraction 
as well as vascular smooth muscle cell growth (Rasmussen et al., 1987; Ruan and 
Arendshorst, 1996a; Oriji and Keiser, 1997; Kirton and Loutzenhiser, 1998). PKC 
activation of the Na+/H+ exchanger and the resultant intracellular alkalinazation 
leads to vasoconstriction in some vascular beds by increasing Na+ and Ca2+ and by 
sensitizing the contractile machinery to Ca2+ (Grinstein et al., 1989; Carr et al., 
1995; Ye, 1996; Tepel et al., 1998; Touyz et al., 1999a) (Figure 1.3). 
 
1.4.5 Activation of Src family kinases 
c-Src (one of at least 14 Src-related kinases identified) is phosphorylated when the 
AT1 receptor is activated, with maximal activation occurring within 60s (Ishida et 
al., 1995, 1998; Marrero et al., 1995; Touyz et al., 1999a). Src plays an important 
role in AT1-induced PLC-γ phosphorylation and IP3 formation. AT1-induced Ca2+ 
concentration responses in human VSMCs are mediated, in part, via Src-dependent 
mechanisms (Touyz et al., 2001). 
 
1.4.6 Phospholipase A2 activation and arachidonic acid metabolism 
In addition to rapid signaling events described above, early signaling processes, 
such as the activation of PLA2 and arachidonic acid (AA) metabolism, are 
simulated by AT1 activation within minutes (Rao et al., 1994). PLA2-derived 
eicosanoids influence vascular mechanisms important in blood pressure regulation, 
by both prohypertensive and antihypertensive mechanisms (Nasjletti, 1998). At 
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least three types of PLA2 exists: a low-molecular-weight (14-15 kDa) calcium-
dependent secreted PLA2 (sPLA2) which are subdivided into three groups (I, II and 
III), a high-molecular-weight (80-160 kDa) calcium-dependent cytosolic PLA2 
(cPLA2), and a calcium-independent PLA2 (iPLA2) (approximately 40 kDa) 
(Dennis, 1997, 1994; Mayer et al., 1993; Clark et al., 1991; Hazen et al., 1990). The 
high specificity of cPLA2 for sn-2-arachidonoyl-containing phospholipids and its 
detection in a large variety of cells suggest that cPLA2 plays an important role in the 
generation of AA-derived signaling molecules, although the involvement of other 
PLA2 cannot be ruled out. Angiotensin II-elicited phosphorylation and activation of 
cytosolic PLA2 (cPLA2) is dependent on intracellular Ca2+, Ca2+-calmodulin-
dependent protein kinase (CaM kinase II) and mitogen-activated protein kinase 
(MAPK) (Muthalif et al., 1998). Ca2+ is not required for cPLA2 activity but serves 
as a stimulus to translocate the enzyme from the cytoplasm to the membrane, where 
its substrate, phospholipids, is localized (Clark et al., 1991). cPLA2 is a substrate for 
MAPK (Lin et al., 1993). MAPK phosphorylates cPLA2 at Ser-505 and recent 
evidence suggests that both CaM kinase II and MAPK are involved in the activation 
of cPLA2 (Clark et al., 1995; Muthalif et al., 1998). The findings also suggest that 
CaM kinase II acts upstream of MAPK in the activation of cPLA2 (Muthalif et al., 
1998).  
 
PLA2 activation results in the release of arachidonic acid (AA) in vascular smooth 
muscle from cell membrane phospholipids (Bonventre, 1992; Rao et al., 1994) 
(Figure 1.3). Released AA is processed by (i) cyclooxygenases to the five major 
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prostanoids, thromboxane A2 (TXA2), prostaglandin (PG) I2, PGE2, PGD2 and 
PGF2α (Smith et al., 1991), (ii) lipooxygenases to hydroxyeicosatetraenoic acids 
(HETEs) and leukotrienes (LT) (Yamamoto et al., 1992), or (iii) cytochrome P450 
oxygenases to epoxyeicosatrieenoic acids, 20- and 19- HETE and other HETEs 
(Harder et al., 1995; Dennis, 1997) (Figure 1.6). 
 
These eicosanoids may act both as intracellular second messengers by modifying 
the activity of intracellular enzymes and ionic channels, and as local mediators 
(autocoids) by being released outside the cell of origin and binding to specific cell 
surface prostanoid receptors of neighbouring cells. TXA2 is produced mainly by 
platelets and contracts smooth muscle and induces platelet aggregation. In contrast, 
PGI2 and PGE2, the major vasodilator prostaglandins produced in the vasculature 
(Hassid and Williams, 1983; Schror, 1993), are produced by vascular endothelial 
and smooth muscle cells and strongly inhibit platelet aggregation (mediated by PGI2 
only) and relax smooth muscle, thus attenuating the vasoconstriction induced by 
angiotensin II (Wilcox and Lin, 1993). The interplay between prohypertensive and 
antihypertensive functions subserved by cyclooxygenase- and lipoxygenase-derived 
eicosanoids determines its modulatory effect on vascular responses to angiotensin. 
Several lines of evidence suggest that the contractile effects of eicosanoids on 
smooth muscle may be mediated by the release of calcium. In contrast, their 
relaxation effects may be mediated by the generation of cAMP via the GS protein 
(Turcato et al., 1999; Ruan et al., 1999; Wise and Jones, 1996), although cAMP 
independent pathways, e.g., activation of ATP-sensitive and Ca2+-activated K+
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 Figure 1.6 Arachidonic acid metabolism. PG: prostaglandin, TX: 
thromboxane, LT: leukotriene, HETE: hydroxyeicosatetraenoic acid. 
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channels (KCa), may be involved (Jackson et al., 1993; Bouchard et al., 1994; 
Schubert et al., 1997; Clapp et al., 1998; Purdy et al., 2001). 
 
1.4.7 PLD activation 
Angiotensin II also activates PLD, which hydrolyzes phosphatidylcholine (PC) to 
choline and phosphatidic acid (Figure 1.3). Angiotensin II coupling to PLD 
activation is suggested to be mediated by Gα12 and Gβγ via pp60c-src- and RhoA-
dependent mechanisms (Ushio-Fukai et al., 1999). In VSMCs, phosphatidic acid is 
rapidly converted to DAG by phosphatidic acid phosphohydrolase, and arachidonic 
acid is generated by the action of diacylglycerol lipase on diacylglycerol (Billah, 
1993). Hence, the sustained PLD activation by angiotensin II plays an important 
role in VSMC signaling, e.g., it contributes, in part, to the sustained production of 
prostaglandins in VSMCs (Gomez-Cambronero et al., 1998). Recent studies using 
rat and rabbit aortic VSMCs suggests that the angiotensin II-induced increase in 
PLD activity is mediated by AA and/or its metabolites generated via cytochrome 
P450 oxygenase and lipoxygenase as a result of cPLA2 stimulation (Shinoda et al., 
1997; Parmentier et al., 2001). These AA metabolites activate PLD via the ras/MAP 
kinase pathway, which releases further arachidonic acid through the phosphatidate 
phosphohydrolase/diacylglycerol lipase pathway. DAG is also the physiological 
activator of PKC. This PLD pathway is the most important source of phosphatidic 
acid and DAG and probably represents the major pathway by which PKC remains 
activated in VSMCs (Lassegue et al., 1993; Dhalla et al., 1997).  
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1.4.8 Modulation of cyclic nucleotides 
Angiotensin II has been shown to increase cyclic nucleotides adenosine 3’,5’-cyclic 
monophosphate (cAMP) and guanosine 3’,5’-cyclic monophosphate (cGMP) 
concentrations directly in VSMCs via activation of vascular or endothelial AT1 
receptors (Hassid, 1986 ; Boulanger et al., 1995; Magness et al., 1996). The cAMP 
and cGMP, which are generated intracellularly within minutes by adenylate cyclase 
and guanylate cyclase, activate downstream targets including cAMP-dependent 
kinase (PKA), cGMP-dependent kinase (PKG), intracellular Ca2+ and ionic 
channels (Bentley and Beavo, 1992). PKA has been shown to phosphorylate the 
calmodulin-binding domain of MLCK (site A) at a specific serine residue in vitro, 
leading to a reduced affinity of MCLK for the Ca2+-calmodulin complex (Conti et 
al., 1981). However, agonists that elevate cAMP in vivo had negligible effects on 
MLCK phosphorylation and Ca2+ desensitization in bovine tracheal smooth muscle 
(Stull et al., 1990), suggesting that cAMP desensitizes smooth muscle by an 
alternative mechanism. PKA and PKG have also been shown to phosphorylate 
RhoA at serine 188 and inactivate RhoA signaling, possibly by inhibiting RhoA 
membrane translocation (Lang et al., 1996, Sawada et al., 2001). Since Rho-kinase 
has been suggested to mediate the inhibition of MLCP (Seko et al., 2003), RhoA 
inactivation increases MLCP activity and decreases Ca2+ sensitivity of 
phosphorylation, leading to decreased myosin phosphorylation and attenuation of 
smooth muscle contraction, or smooth muscle relaxation, upon agonist stimulation.  
PKG was also shown to activate MLCP directly by phosphorylating the myosin 
binding site of MLCP via a leucine zipper interaction (Lee et al., 1997; Surks et al., 
 36
1999). In addition, other proposed mechanisms of cyclic-nucleotide-dependent 
vasorelaxation include decreasing intracellular Ca2+ (McDaniel et al., 1991), 
phosphorylation of IP3 receptor (Komalavilas et al., 1996) and phospholamban, an 
inhibitor of smooth muscle sarcoplasmic reticulum Ca2+-ATPase (Lincoln and 
Cornwell, 1991), activation of plasma membrane Ca2+-ATPase (Kimura et al., 
1982; Furakawa et al., 1988) and KCa, the latter inducing hyperpolarization and 
reducing Ca2+ influx as a result of closure of voltage-gated L-type Ca2+ channels 
(Thornbury et al., 1991; Schubert et al., 1996; Orlov et al., 1999). 
 
1.4.9 Tyrosine kinase phosphorylation 
 It has recently become apparent that tyrosine phosphorylation plays an important 
role in the signaling pathways of the AT1 receptor despite the fact that the AT1 
receptor, unlike most growth factor receptors, harbors no intrinsic kinase activity. 
Tyrosine phosphorylated proteins in VSMC include the AT1 receptor itself, PLC-γ 
and Src family kinases, as well as JAK and TYK, FAK, Pyk2, p130cas, and 
phosphatidylinositol 3-kinase (PI3K). Only Fyn and c-Src of the Src family kinases 
are expressed in VSMC (Sayeski et al., 1998). The net effect of tyrosine 
phosphorylation, and thus activation, of Fyn and c-Src is the subsequent facilitation 
of guanine nucleotide exchange of Ras-GDP to Ras-GTP (i.e. Ras activation) via 
the Shc-Grb2-Sos pathway (Schieffer et al., 1996; Sadoshima and Izumo, 1996). 
Activated Ras-GTP interacts with the Ser/Thr kinase Raf (mitogen-activated protein 
kinase kinase kinase (MAPKKK)), which translocates to the cell membrane. Raf 
phosphorylates MAPKK (MAPK kinase), which in turn activates MAPK. Once 
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phosphorylated, MAPKs translocate to the nucleus to phosphorylate transcription 
factors and thereby regulate gene expression of cell cycle-related proteins 
(Treisman, 1996). 
 
JAKs are key mediators of mRNA expression. JAKs accomplish this by 
phosphorylating the signal transducers and activators of transcription (STATs). 
Phosphorylated STATs translocate to the nucleus where they bind to Sis-inducible 
promotor elements and stimulate transcription of the early growth response genes 
such as c-fos, c-jun and c-myc. Studies have now shown that angiotensin II directly 
activates the JAK/STAT pathway via the AT1 receptor and this may be a 
mechanism whereby angiotensin II influences vascular growth, remodeling and 
repair (Berk and Corson, 1997; Hefti et al., 1997).  
 
Angiotensin II rapidly activates FAK in VSMCs (Polte et al., 1994). Upon 
phosphorylation, FAK translocates to focal adhesions where it phosphorylates 
substrates such as paxillin and p130cas, thus promoting cytoskeletal arrangement 
(Burridge et al., 1992). The tyrosine phosphorylation of paxillin correlates 
temporally with the formation of focal adhesion contacts in VSMCs and suggests 
that FAK may play a role in coordinating VSMC proliferation/remodeling with 
changes in cell structure (Turner et al., 1995). On the other hand, the tyrosine 
phosphorylation of p130cas correlates temporally with its ability to bind at least 11 
different phosphate-containing proteins in response to angiotensin II, supporting the 
concept that it is an adaptor molecule. Three of the 11 proteins have been identified 
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as c-Src, PKCα and the integrin signaling molecule pp120. Thus, it appears that 
p130cas serves as a convergence point for three very different signaling pathways, 
namely, the c-Src tyrosine kinase pathway, the Ser/Thr PKC pathway, and the cell 
adhesion-mediated pp120 pathway. 
 
Of the many GPCRs, the AT1 receptor seems to be one of the most important in 
vascular smooth muscle cell regulation. Exact reasons for the apparent selective 
importance of angiotensin II actions via AT1 receptors are unclear but may be due 
to the ability of angiotensin II to amplify its vascular responses via other agonists. 
Angiotensin II stimulates production of growth factors, e.g., platelet-derived growth 
factor (PDGF), and vasoactive peptides, e.g., endothelin-1 (ET1), as well as 
transactivates multiple receptors, such as PDGF receptor and epidermal growth 
factor receptor (Kim and Iwao, 2000), thereby amplifying VSMC signaling 
responses to angiotensin II. The end result, contraction, hypertrophy, or 
proliferation, is determined by the selective activation of multiple signaling 
pathways, and the phenotype of the stimulated VSMC.  
 
1.5 Functional and Structural Complexity of Signal Transduction via 
GPCRs 
AT1 and AT2 receptors belong to the GPCR superfamily, which utilizes 
heterotrimeric GTP-binding proteins (G proteins) to govern effector proteins. The 
AT1 receptor, like other GPCRs, has been proposed to spontaneously isomerize 
between its inactive (R) and active (R*) states as described in the extended ternary 
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complex model (Samama et al., 1993; Chidiac et al., 1994). In the absence of 
agonists, the receptor is preferentially maintained in an inactive R conformation by 
stabilizing intramolecular interactions, as evidenced by the constitutive activity of 
mutated AT1 receptors (Noda et a., 1996; Groblewski et al., 1997; Balmforth et al., 
1997). Binding of angiotensin II presumably selects or induces an active R* 
conformation that initiates intracellular signaling (Noda et al., 1995).  
 
It has become apparent that the vascular AT1 receptor is able to couple to multiple 
signal transduction pathways, with temporal organization of the disparate signals. 
The exact mechanism by which a single AT1 receptor is able to do this is unclear.  
Recent evidence suggests that the activated AT1 receptor undergoes several 
transitions into multiple conformational states and this has been postulated as a 
mechanism for coupling to multiple signal transduction pathways. For example, it 
has been shown that the agonist-induced activation of the AT1 receptor appears to 
be triggered by an initial interaction between Tyr4 residue of angiotensin II and the 
Asn111 residue located in the third transmembrane domain of the receptor (Noda et 
al., 1996). The interaction of Phe8 of angiotensin II with His256 in the sixth 
transmembrane domain of the receptor then appears to drive the AT1 receptor into 
its fully active R* state (Noda et al., 1995). Thomas et al. (2000) also demonstrated 
that the conformation of the activated AT1 receptor for receptor phosphorylation is 
distinct from the conformation required for inositol phosphate signaling. Evidence 
for conformational selection has also been reported with other GPCRs, including 
the human 5-HT2C receptor, PACAP receptors and dopamine D2 receptors (Meller 
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et al, 1992; Splengler et al., 1993; Berg et al., 1998), suggesting that this could be a 
common mechanism for coupling of GPCRs to multiple signal transduction 
pathways. 
 
This proposed mechanism of receptor activation has several important implications. 
Firstly, it may explain how a single receptor may couple to multiple G proteins 
since different conformational states of R* may provide a structural means of 
differentially coupling to different G proteins to mediate different effector 
pathways, resulting in subtle differences of response of a single receptor to different 
agonists.  
 
Secondly, it may explain why different agonists, e.g., angiotensin IV, can have 
different efficacy by their ability to preferentially select for one of several receptor 
conformations through their ligand structure (Le et al., 2002). The preferred 
conformation may couple with low efficacy to G proteins or may selectively 
activate a subset of the multiple signal transduction pathways that may be coupled 
to a single receptor subtype. This phenomenon is also known as agonist-directed 
trafficking of receptor signals (Kenakin, 1995). 
 
In addition, as in many other GPCRs, it was recently demonstrated that the AT1 
receptor can assemble with the bradykinin receptor to form heterodimers, resulting 
in enhanced G protein activation and altered receptor sequestration (AbdAlla et al., 
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2000). The heterodimerization of the AT1 receptor with other receptors may provide 
an additional mechanism of cell-specific regulation of angiotensin responses.  
 
1.6 Role of RAS in Primary Pulmonary Hypertension (PPH) 
Primary pulmonary hypertension (PPH) is a rare and serious disease of unknown 
cause characterized by abnormally high pressure in the pulmonary artery in the 
absence of secondary causes. The pathogenesis of PPH is currently not clearly 
understood. However, there is evidence to suggest that a genetic susceptability and 
an imbalance in endothelium-derived vasoconstrictors and vasodilators resulting 
from endothelial cell injury are involved (Runo et al., 2003). The increased vascular 
resistance seen in PPH has been attributed to two major factors:  1) vasoconstriction 
and 2) thickening or remodeling of the vascular arterial wall.  There is also a 
tendency for blood clots to form within the small vessels. 
 
Studies in PPH patients have shown an imbalance in the ratio of the metabolites of 
prostacyclin and thromboxane (Christman et al., 1992). Other studies have shown 
an impaired synthesis of the endothelial-derived vasodilator, nitric oxide, that could 
be due to a reduced level or activity of nitric oxide synthetase (Giaid et al., 1995).  
Endothelin, a potent endothelial-derived vasoconstrictor, has been found to be at 
abnormally high levels in PPH patients (Giaid et al., 1993). Current standard 
therapies for PPH include the use of calcium channel blockers (nifedipine, 
diltiazem), continuous intravenous epoprosternol (PGI2) or lung transplantation. 
However, calcium channel blockers are only effective in about 30% of patients. 
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Epoprosternol remains the most effective therapy for PPH with majority of patients 
responding favourably to the treatment (Runo et al., 2003). Because the half-life of 
epoprosternol is short, continuous intravenous delivery and placement of a long-
dwelling catheter are necessary. As a result, complications from the delivery 
system, including exit-site infections and bleeding, paradoxical embolism, 
bacteraemia or sepsis, and delivery malfunction that may result in sudden, in some 
cases fatal, decompensation may occur.  Therefore, there is an urgent need for 
improved treatment modalities for the management of PPH and drugs currently in 
clinical development include inhaled iloprost (PGI2 analog), endothelin ET-1 
receptor antagonist (bosentan, sitaxsentan), phosphodiesterase inhibitors (sildenafil) 
and thromboxane synthase inhibitors and receptor antagonists.  
 
There is recent evidence to suggest that the RAS may have a role in the 
pathogenesis of PPH. Orte et al. (2000) demonstrated an increased expression of 
endothelial angiotensin-converting enzyme in the intra-acinar arteries in patients 
with PPH. Schuster et al. (1996) similar demonstrated increased ACE 
immunoreactivity in the endothelium and sub-endothelial neointimal regions of 
pulmonary arteries from PPH patients, suggesting that locally produced angiotensin 
II may contribute to the pathogenesis of PPH. In addition, irbesartan, an AT1 
receptor antagonist, was recently shown to prevent lung structural remodeling and 
pulmonary hypertension following myocardial infarct in rats (Jasmin et al., 2003). 
The role of RAS in the pathogenesis of PPH and the potential development of 
therapies targeting the RAS for the management of PPH awaits further clarification. 
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 1.7 Conclusion 
The RAS is a highly complex system that generates pleiotropic effects in many 
target organs, including the brain, kidneys and vasculature. The recent successful 
clinical use of ACE inhibitors and AT1 receptor antagonists suggests the importance 
of the RAS in the pathophysiology of many cardiovascular diseases. Most of the 
known effects of the RAS are mediated through the AT1 receptor. The recent 
demonstration that there are several pathways for degradation of angiotensin I and 
angiotensin II leading to different bioactive fragments with their own binding sites 
raises the question of the relative importance of these pathways in fine-tuning or 
regulating angiotensin responses. The recent report of functionally distinct AT1 
receptor isoforms derived from alternative splicing of a single AT1 gene, differing 
in a 32 amino acid amino terminal extension, raises the possibility that angiotensin 
II responsiveness can be fine-tuned by regulating the relative expression of the long 
and short isoforms in a given tissue. Additionally, a single GPCR can couple to 
multiple G proteins and signal transduction pathways. All three levels of 
complexity can contribute to a cogent response to fine-tune angiotensin responses. 
Although there has been significant progress in the elucidation of angiotensin-
induced signal transduction, which is mediated by G proteins, it still remains 
unclear how receptors direct specificity and coordination of multiple signals to 
produce a desired concerted response. Understanding how G proteins coordinate 
these responses would perhaps help shed some light on the complexities of 
angiotensin signal transduction. 
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CHAPTER 2 
FUNCTIONAL STUDIES ON ISOLATED RABBIT 
PULMONARY TRUNK AND ARTERY 
 
2.1 Introduction 
The angiotensin receptors are classified into two main types, namely the angiotensin 
AT1 and angiotensin AT2 receptors (de Gasparo et al., 2000).  Based on the 
existence of two separate cDNAs for the angiotensin AT1 receptor, the receptor is 
known to consist of the two subtypes, AT1A and AT1B receptors (Kakar et al., 
1992a; Iwai et al., 1992).  Both of these subtypes are blocked by losartan but not by 
PD123319, which selectively blocks angiotensin AT2 receptors.  VSMCs express 
primarily AT1A receptors and they have been suggested to mediate vascular smooth 
muscle constriction.  The angiotensin AT1B receptor subtype does not seem to 
mediate vasoconstriction in vascular tissue, it being found in the brain, pituitary and 
adrenal glomerulosa (Kakar et al., 1992b). 
 
Two recent functional studies in our laboratory using des-Asp-angiotensin I indicate 
that the rabbit pulmonary trunk and artery contain two functionally opposing 
subtypes of the losartan-sensitive angiotensin AT1 receptor (Sim and Soh, 1995; 
Sim and Chai, 1996).  The pulmonary artery contains predominantly one of the 
receptor subtypes, which mediated contraction of the pre-contracted artery by des-
Asp-angiotensin I and is identifiable with the angiotensin AT1A receptor.  The other 
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receptor subtype is found to co-exist with the former in the pulmonary trunk and 
mediates relaxation of the preconstricted artery.  In addition to its susceptibility to 
losartan, this other subtype is indomethacin-sensitive and is suggested to be 
identifiable with the angiotensin AT1B receptor described by Kakar et al. (Kakar et 
al., 1992b; Iwai et al., 1992).  These studies show for the first time the likely 
function of the AT1B-like receptor subtype and the vasorelaxant action of an 
endogenous angiotensin.  The existence of the angiotensin AT1B-like receptor in the 
pulmonary trunk has been supported in a recent binding study (Sim and Lim, 1998).  
The purpose of the present study was therefore to further investigate the two 
receptor subtypes using additional angiotensin peptide fragments, namely 
angiotensin II, angiotensin III, angiotensin IV, angiotensin (1-7), angiotensin (4-8), 
and angiotensin (3-7) and to decipher the possible roles the receptors may have in 
regulating blood flow from the heart to the lung. In addition, the structure-activity 
relationship of angiotensin IV was also investigated. 
 
2.2 Materials and Methods 
2.2.1 Isolation of rabbit pulmonary trunk and artery 
The pulmonary trunk and arteries of male albino rabbits weighing 1.5 – 2.5 kg 
supplied by local University Animal Centre were used throughout the study. Each 
rabbit was killed by either cervical dislocation or carbon dioxide poisoning. No 
difference in response was found with both methods of killing. The pulmonary 
trunk (the vessel arising from the right ventricle prior to its bifurcation into the left 
and right pulmonary arteries) and the two pulmonary arteries (vessels distal to 
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bifurcation) were rapidly removed and transferred into freshly prepared Krebs 
solution (118mM NaCl, 5mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 2.5mM 
CaCl2.2H2O, 25mM NaHCO3, 10mM glucose.H2O, 0.026mM EDTA, 0.3mM 
ascorbic acid) presaturated with carbogen (95% oxygen, 5% carbon dioxide). 
Connective and adipose tissue surrounding the vessels were gently removed.  
 
2.2.2 Preparation of pulmonary trunk and artery strips 
The isolated pulmonary trunk and arteries were cut transversely into 3mm rings. 
The rings were cut open into strips and were denuded of endothelium by gently 
rubbing the luminal surface with cotton buds. The rationale for the use of an 
endothelium-denuded preparation was to allow for the investigation of the 
physiological effects of angiotensin peptides in a clean vascular smooth muscle 
preparation without the interference of endothelium-derived factors. 
 
The ends of the strips were secured with suture and suspended under an optimal 
resting load of 2 g in a 20 ml organ bath maintained at 37oC containing Krebs 
solution presaturated with carbogen. Contractions were recorded isometrically with 
an Ugo Basile isometric transducer attached to a MacLab/8 Virtual Instrument via a 
MacLab Quad Bridge Amplifier. A 60-minute equilibration period was allowed 
before any experimentation was begun. 
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2.2.3 Direct actions of angiotensin peptides 
After equilibration, a non-cumulative dose response for each of the five angiotensin 
peptides tested (angiotensin II, angiotensin III, angiotensin IV, angiotensin (1-7) 
and angiotensin (4-8)) was obtained. This was done by adding increasing 
concentrations of each angiotensin peptide to the pulmonary trunk and artery strips. 
For each concentration, contractions were allowed to reach their maxima. A 30-
minute washout and rest period was allowed before the next concentration of the 
angiotensin peptide was added. The non-cumulative dose response was done to 
determine the threshold and optimal concentration of the angiotensin peptides on 
noradrenaline-contracted pulmonary trunk and artery strips.  
 
The effects of 1 µM losartan, an AT1-selective receptor antagonist, on the response 
to maximal-effect concentrations of 100 nM angiotensin II, 1 µM angiotensin III 
and 10 µM angiotensin IV were studied by pre-incubating the strips with losartan 
for 30minutes prior to addition of the peptides.  
 
At the end of the experiment, each strip was contracted with 60 mM KCl. This was 
defined as the maximum tissue response and all contractions to angiotensins were 
expressed as a percentage of this maximum response. 
 
2.2.4 Effects of angiotensin peptides on pre-contracted trunk and artery strips 
Following equilibration, the sections were pre-contracted with 100 nM 
noradrenaline. After the contractions had reached a steady plateau (at 5 minutes), 
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each of the five angiotensin peptides was added and the response observed for a 
further 5 minutes.  The tissue was pre-contracted to produce an elevated contractile 
tone so that any relaxation to the angiotensin peptides could be observed. In this 
experiment, the effect of angiotensin (3-7) on the pre-contracted trunk and artery 
strips was also studied. 
 
At the end of the experiment, the sections were contracted with 100 nM 
noradrenaline.  This was followed by the addition of 1 µM acetylcholine to test the 
extent of endothelial denudation.  All sections contracted to acetylcholine, 
indicating that the sections were completely denuded of endothelium. 
 
2.2.5 Effects of receptor antagonists and enzyme inhibitors 
To characterize the receptor subtypes mediating the response of the precontracted 
strips to angiotensins, the strips were pre-incubated with 1 µM losartan (selective 
AT1 receptor antagonist) or 1 µM PD123319 (selective AT2 receptor antagonist) 
during the 30-minute washout and rest period. The effects of the receptor 
antagonists on the actions of angiotensin II, angiotensin III and angiotensin IV (the 
peptides found to be vasoactive) were studied.  
 
To determine the involvement of prostaglandins, 10 µM indomethacin (non-
selective cyclooxygenase inhibitor) was used in place of losartan and PD123319. 
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To investigate if angiotensin metabolites contributed to the response observed, 
pulmonary tissue was similarly pre-incubated with 30 µM amastatin (a selective 
aminopeptidase A and N inhibitor). 
 
The effect of 1 µM divalinal-angiotensin IV (putative selective AT4 antagonist) on 
angiotensin IV-induced relaxation in pre-contracted pulmonary trunk strips was also 
determined.  
 
2.2.6 Structure-activity relationship of angiotensin IV  
To determine the structure activity relationship of angiotensin IV, six glycine-
substituted analogs of angiotensin IV (each of the six amino acids in angiotensin IV 
was substituted by glycine, in turn) were added to noradrenaline pre-contracted 
rabbit pulmonary trunk and artery strips as previously described. The responses of 
the strips to each of the six angiotensin IV analogs were observed. To explore if 
these analogs had any antagonistic actions, the tissue strips were preincubated with 
each analog for 30 minutes before angiotensin IV was added to noradrenaline-
precontracted tissue. 
 
2.2.7 Expression of results 
The contraction from the resting tension caused by 100 nM noradrenaline was 
defined as the control contraction and the effect of each angiotensin on the pre-
contracted section was expressed as a percentage change of this control contraction.  
The concentrations of vasoactive angiotensins used in this particular study were 
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based on the results of a preliminary concentration response experiment.  The 
concentrations chosen for angiotensin II (100 nM), angiotensin III (50 nM) and 
angiotensin IV (5 µM) were based on the reproducibility of responses with each 
concentration. 
 
2.2.8 Statistical analysis 
The data is presented as means ± standard error of mean (SEM) for n observations.  
The influences of losartan, PD123319 and indomethacin on the action of 
angiotensin peptides on the pre-contracted trunk and artery sections were analysed 
using ANOVA with Tukey’s multiple range test for a posteriori comparisons.   
 
2.3 Results 
2.3.1 Direct actions of angiotensin peptides 
Of the 5 angiotensin peptides tested, angiotensin (1-7) and angiotensin (4-8) were 
not vasoactive in these experiments. Angiotensin II, angiotensin III and angiotensin 
IV induced greater contractions in the rabbit pulmonary artery than in the 
pulmonary trunk with angiotensin II being the most potent and angiotensin IV the 
least (Figure 2.1). 10-6 M losartan but not 10-7 M PD123319 inhibited the maximum 
actions of the angiotensins in the arterial and trunk sections indicating that the 








9.3  9  8.3  8  7.3   7         9 8.3  8  7.3  7   6.3  6       6   5.3  5              9  8.3  8  7.3  7         8  7.3  7   6.3      6  5.3  5




Pulmonary Artery                                                Pulmonary Trunk















Figure 2.1 Direct contractile actions of angiotensin II (Ang II), 
angiotensin III (Ang III) and angiotensin IV (Ang IV) on the rabbit 
pulmonary artery and pulmonary trunk. Each histogram gives the mean 
± SEM of 3 experiments. 
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2.3.2 Effects of angiotensin peptides on pre-contracted trunk and artery strips 
Of the 6 angiotensin peptides tested, Ang(1-7), Ang(4-8) and Ang(3-7) were not 
vasoactive in these experiments. In the pre-contracted pulmonary artery strips, 
angiotensin II and angiotensin III further contracted the strips, while angiotensin IV  
had no effect.  In contrast, in the pre-contracted pulmonary trunk, angiotensin II 
further contracted the strips while angiotensin III and angiotensin IV relaxed the 
pre-contracted strips (Figure 2.2).   
 
2.3.3 Effects of receptor antagonists and enzyme inhibitors 
Losartan, but not PD123319, inhibited the relaxation and further contraction of the 
pre-contracted strips to angiotensin II, angiotensin III and angiotensin IV, indicating 
that their actions were mediated by the angiotensin AT1 receptor.  Indomethacin 
inhibited only the relaxation induced by angiotensin III and angiotensin IV, 
suggesting that the relaxation by these peptides were mediated by a prostaglandin-
coupled angiotensin AT1 receptor subtype (Figure 2.3).   
 
Initial experiments indicated that angiotensin II further contracted both pre-
contracted pulmonary trunk and artery, with the contraction seen in the artery of a 
greater magnitude compared to that seen in the trunk. However, in further 
experiments, it was observed that angiotensin II relaxed 6 out of 16 pre-contracted 
pulmonary trunk strips (Figure 2.4). In these experiments, amastatin significantly 
increased angiotensin III-induced further contraction of pre-contracted pulmonary 

































Figure 2.2 Effect of angiotensin II (100 nM), angiotensin III (50 nM) 
and angiotensin IV (5 µM) on the noradrenaline pre-contracted rabbit 
pulmonary artery and pulmonary trunk. Each histogram gives the 
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Figure 2.3 Influence of losartan (1 µM) and indomethacin (10 µM) on 
responses to angiotensin II, angiotensin III and angiotensin IV in the 
noradrenaline pre-contracted rabbit pulmonary artery and pulmonary trunk. 
Each histogram gives the mean ± SEM of 3 experiments. *significantly 
different from angiotensin-induced response. 
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 trunk. In contrast, amastatin did not significantly affect the responses of pre-
contracted strips to angiotensin II and angiotensin IV (Figure 2.4). Divalinal-
angiotensin IV did not have any significant effect on angiotensin IV-induced 
relaxation of pre-contracted pulmonary trunk, indicating AT4 receptors did not 
mediate the relaxant response (Figure 2.5). 
 
2.3.4 Structure-activity relationship of angiotensin IV 
There were no agonist and antagonist properties observed with the 6 glycine-
substituted analogs of angiotensin IV when these analogs were added to pre-
contracted trunk and artery strips.  
 
2.4 Discussion 
The present data demonstrate the differential responses of the rabbit pulmonary 
trunk and artery to angiotensin III and angiotensin IV, and lend support to an earlier 
finding that the rabbit pulmonary trunk and artery contain two losartan-sensitive 
angiotensin receptor subtypes (Sim and Lim, 1998).  The AT1A-like subtype that 
mediates contraction is found predominantly in the pulmonary artery while the 
pulmonary trunk contains a mixture of AT1A-like and AT1B-like subtypes (Sim and 
Lim, 1998); the latter subtype has been shown to mediate relaxation (Sim and Chai, 
1996).  This unusual distribution of functionally opposing receptor subtypes and the 
different affinity of each receptor subtype for the four vasoactive angiotensins 
(angiotensin II, angiotensin III, angiotensin IV and des-Asp-angiotensin I) probably 
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Figure 2.5 Influence of divalinal-angiotensin IV (DV-AngIV) (1uM) on 
the responses to angiotensin IV in the noradrenaline pre-contracted rabbit 
pulmonary artery and trunk. Each histogram represents the means ±
SEM of 3 experiments. Asterisk indicates response is significantly different 
from control.  
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to angiotensin-(1-7) would indicate that the heptapeptide does not act on the two 
receptor subtypes.  This is not unexpected as the known vascular actions of the 
angiotensin-(1-7) are  quite   different from those of angiotensin II and angiotensin 
 III. Angiotensin-(1-7) has antihypertensive and vasodilatory actions and these 
actions were attenuated following inhibition of nitric oxide synthetase (Osei et al., 
1995; Nakamoto et al., 1995).  It has recently been shown to act on a new 
angiotensin receptor (Santos et al., 1994).  Angiotensin-(4-8) and angiotensin-(3-7) 
are not known to be vasoactive and are shown to be the case in this study.  Although 
angiotensin IV has been known to act on the AT4 receptor (Krebs et al., 1996), it is 
unlikely that the AT4 receptor mediates the actions of angiotensin IV seen in this 
study.  This is because its actions were blocked by losartan and not by divalinal-
angiotensin IV.  The weak contractile action of angiotensin IV seen in the arterial 
section could be due to its poor affinity for the AT1A receptor or its degradation by 
tissue peptidases. 
 
At the trunk section where both the AT1A-like and AT1B-like receptors have been 
shown to be present in comparable density (Sim and Lim, 1998), the response seen 
with each angiotensin would be a resultant action of the peptide on the composite 
receptor subtypes.  Angiotensin IV induced feeble direct contractile response in the 
trunk section.  The responses to angiotensin II and angiotensin III were about a 
quarter and a sixth, respectively, of those seen in the arterial sections.  The lower 
number of AT1A-like subtypes present in the trunk section (Sim and Lim, 1998) 
could have contributed to the lower responses.  However, the AT1B-like receptors 
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could also have contributed to the diminution of the responses especially in the case 
of angiotensin III and angiotensin IV where the response was a sixth and a tenth, 
respectively, of those seen in the arterial sections. Both angiotensin III and 
angiotensin IV attenuated the contraction induced by noradrenaline, whereas 
angiotensin II increased the level of contraction albeit to a lesser extent than in the 
arterial section.  These different responses are probably caused by angiotensin II 
having a higher affinity for the AT1A-like over the AT1B-like subtypes while the 
reverse holds true for angiotensin III and angiotensin IV.  Applied to other vascular 
tissues where a mixture of AT1A and AT1B receptors is also likely to be present, it 
would be expected that angiotensin III and angiotensin IV would always be weaker 
pressors. 
 
Amastatin, a selective aminopeptidase A and N inhibitor (Ahmad and Ward, 1990), 
attenuated angiotensin III-induced relaxation of noradrenaline pre-contracted 
pulmonary trunk and enhanced the angiotensin III-induced further contraction of the 
pre-contracted pulmonary artery. This suggests that the angiotensin III-induced 
further contraction and relaxation of pre-contracted pulmonary artery and trunk, 
respectively, are mediated in part by a breakdown product of angiotensin III. 
Angiotensin IV is a likely candidate for this breakdown product since angiotensin 
III is broken down by APN to generate angiotensin IV (Kugler, 1982; Palmieri et 
al., 1989). In addition, the metabolites of angiotensin IV are not known to be active 
(Chansel et al., 1998).  
 
 60
The presence of two functionally opposing angiotensin receptor subtypes in the 
short pulmonary trunk and artery may suggest that the vessel is not just a passive 
conduit but may be an important regulator of blood flow from the heart to the lung.  
Further increase in vascular tone by angiotensins at the arteries may slow entry of 
blood into the lung and lower the blood pressure post arterially.  Decrease of 
vascular tone by angiotensins at the pulmonary trunk may dampen the pulse without 
producing excessive back pressure on the heart. Understanding the physiological 
protective mechanisms for the fine control of pulmonary blood flow can have 
important therapeutic implications for the development of targeted therapies in 



























RECEPTOR BINDING STUDIES 
 
3.1  Introduction 
Functional studies (chapter 2) demonstrated differential responses of the rabbit 
pulmonary trunk and artery to angiotensin III, des-Asp-angiotensin I (Sim and Soh, 
1995; Sim and Chai, 1996), and angiotensin IV; the three angiotensin peptides 
caused a vasodilator response in the noradrenaline-contracted pulmonary trunk 
while they were either inactive (e.g. angiotensin IV) or caused a further 
vasoconstrictor response in the noradrenaline-contracted pulmonary artery. 
Losartan blocked both the vasoconstrictor and vasodilator response while 
indomethacin blocked only the vasodilator response. In the present study, we 
determined the binding characteristics of the angiotensin receptors in the trunk and 
arterial sections of the rabbit pulmonary artery. 
 
Two different sets of competition binding studies were performed, one using 125I-
Sar1-Ile8-angiotensin II and the other using 125I-angiotensin IV as the radioligand. 
125I-Sar1-Ile8-angiotensin II was selected because it binds to both subtypes of 
receptors in the rabbit pulmonary trunk and main arteries with high affinity; it 
blocked both the vasoconstrictor and vasodilator response to active angiotensins at a 
concentration of 1 nM, 125I-angiotensin IV was selected because organ bath 
experiments indicate that angiotensin IV may have selectivity for the receptor 
mediating vasodilation; it caused a vasodilator response in the noradrenaline-
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contracted pulmonary trunk via an AT1 receptor but had negligible response in the 
main arteries, albeit at a high concentration of 10 µM. 
 
The purpose of the receptor binding studies was to characterize the receptor 
subtypes that mediate the opposing vasodilator and vasoconstrictor response in the 
pulmonary trunk and artery, respectively. We wanted to find out if different 
subtypes of the AT1 receptor mediated the opposing responses. Our experiments 
also addressed the possibility that within either the trunk or the artery, the response 
seen is a composite result of more than one receptor subtype, hence providing a 
possible explanation for the observed differential responses. 
 
3.2  Materials and Methods 
3.2.1 Membrane preparation 
Male or female New Zealand White rabbits were supplied by the local University 
Animal Centre. Six rabbits were killed by carbon dioxide poisoning. The rabbit 
pulmonary trunk and artery were rapidly removed and placed in ice-cold Krebs 
buffer saturated with carbogen (95% oxygen, 5% carbon dioxide). Adhering tissue 
was removed and vessel was denuded of endothelium by gently rubbing a cotton 
bud over its luminal surface.  
 
The trunk and artery were weighed, minced and homogenized in 20 volumes of ice-
cold homogenization buffer (50 mM Tris, 0.25 M sucrose, 5 mM EDTA, 0.1 mM 
PMSF, 0.1 mM 1,10-phenanthroline adjusted to pH 7.4 at 4oC) using a glass 
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homogeniser with a Teflon plunger (4000 rpm, 4 x 30 strokes). The homogenate 
was centrifuged at 700 g for 15 minutes at 4oC, the supernatent obtained filtered 
through two layers of fine cheesecloth and kept on ice, and the pellet resuspended in 
20 volumes of homogenization buffer, rehomogenized (4000 rpm, 3 x 30 strokes) 
and recentrifuged as before. The second filtered supernatent was combined with the 
first and centrifuged at 55,000 g for 45 minutes at 4oC. The supernatent was 
discarded and the pelleted membranes were then resuspended in storage buffer (50 
mM Tris, 5 mM MgCl2.6H20, 5 mM EDTA, 0.1 mM PMSF, 0.1 mM 
phenanthroline, 2 mg/ml BSA, 1 mg/ml bacitracin adjusted to pH 7.4 at either 15oC 
for 125I- Sar1-Ile8-angiotensin II binding or 37oC for 125I-angiotensin IV binding) by 
passing the membrane suspension through a 25-guage needle for 20 times, to a 
concentration of 250 µg protein/ml. 
 
The membranes were stored in liquid nitrogen until subsequent use. Protein 
concentration was determined using the Bio-Rad assay (Bio-Rad Protein Assay, 
Bio-Rad Laboratories, Richmond, CA, USA) using BSA as a standard. The average 
protein yield was about 3.8 (trunk) and 2.8 (artery) mg protein per g of wet tissue. 
 
3.2.2 125I- Sar1-Ile8-angiotensin II competition binding experiments 
Trunk and artery membranes (10 µg protein) were incubated in duplicate with 0.02 
nM 125I-Sar1-Ile8-angiotensin II and increasing concentrations of competing ligands 
at 15oC in a total volume of 100 µl of assay buffer (50 mM Tris, 5 mM 
MgCl2.6H2O, 5 mM EDTA, 0.1 mM 1,10-phenanthroline, 0.1 mM PMSF, 2 mg/ml 
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bovine serum albumin, 1 mg/ml bacitracin, 50 µM Plummer’s inhibitor, 20 µM 
bestatin, 20 µM amastatin, pH 7.4 at 15oC, freshly prepared) for 60 minutes, in 
accordance to previously published protocols (Sim et al., 1998) with slight 
modifications. Non-specific binding was determined in the presence of 1 µM 
unlabeled Sar1-Ile8-angiotensin II, and was approximately 10% of total binding. The 
receptor binding reaction was terminated by centrifugation at 27,500 g for 30 
minutes at 4oC followed by three rapid washes with 0.4 ml ice-cold 50 mM Tris 
buffer, pH 7.4 at 4oC. Radioactivity trapped in the tissue pellet was determined 
using a Packard Cobra II automated gamma counter with 72% efficiency. 
Competing ligands used include angiotensin II, angiotensin III, angiotensin IV, des-
Asp-angiotensin I, Sar1-Ile8-angiotensin II, losartan, PD123319 and divalinal-
angiotensin IV. 
 
3.2.3 125I-angiotensin IV association binding experiments 
To determine how long it takes to reach equilibrium, association binding 
experiments were performed in the presence of 1 nM 125I-angiotensin IV over a 
time course of 300 minutes, with specific binding determined for triplicate samples 
at various time intervals. 125I-angiotensin IV association binding curves reached a 
plateau at approximately 120 minutes which was maintained for at least an 
additional 180 minutes, suggesting that minimal receptor and/or 125I-angiotensin IV 
degradation had occurred. This was confirmed by HPLC analysis of 125I-angiotensin 
IV following 120 minute incubation at 37oC with membranes. The unbound 125I-
angiotensin IV in the supernatant was separated by HPLC and the radioactivity was 
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directly quantitated by a Beckman radioisotope detector (Model 710) as previously 
described (Sim and Manjeet, 1990). Briefly, 10 µl of supernatent (after incubation 
mixture was centrifuged) was resolved through a Merck 5 µm C18 column and the 
125I-angiotensin IV eluted by gradient chromatography (from 0.1% trifluoroacetic 
acid to 70% acetonitrile, 0.085% trifluoroacetic acid). Controls showed that under 
the incubation conditions, more than 90% of the radioligand remained intact.
 
3.2.4 125I-angiotensin IV competition binding experiments 
Trunk and artery membranes (10 µg protein) were incubated in duplicate with 1 nM 
125I-angiotensin IV and increasing concentrations of competing ligands at 37oC in a 
total volume of 100 µl of assay buffer (pH 7.4 at 37oC, freshly prepared) for 120 
minutes. Non-specific binding was determined in the presence of 100 µM unlabeled 
angiotensin IV and was approximately 40% of total binding. The binding reaction 
was terminated and radioactivity counted as before. 
 
3.2.5 Data analysis 
Competition binding data were analyzed using GraphPad Prism. Unless otherwise 
stated, each data point reflects the results from three experiments conducted in 
duplicate. This number of experiments for each data point was limited because of 
the low protein yield from pulmonary trunk and artery tissue, and the considerable 
cost of 125I-angiotensin IV. For example, tissue from six rabbits yielded 
approximately 800 µg protein, which generally was only sufficient for 4 complete 
radioligand binding experiments. 
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 The Kd of angiotensin IV for the receptor and the Bmax in the trunk and artery was 
determined using results from the homologous competitive binding experiment, i.e. 
using angiotensin IV as the radioligand and competing ligand; the low affinity of 
angiotensin IV for the receptor rendered the cost of 125I-angiotensin IV prohibitive 
for a saturation analysis. Similar Kd and Bmax values were determined for the 125I-
Sar1-Ile8-angiotensin II binding site and compared to those obtained previously 
(Sim et al., 1998).  
 
3.2.6 Statistical analysis 
The statistical significance of differences between the Ki values of trunk and artery 
membranes were analyzed using the independent t-test, with p values less than 0.05 
considered significant. For example, the Ki value of 125I-Sar1-Ile8-angiotensin II 
competition binding using AngII as the competing ligand in trunk membranes was 
compared to the Ki value obtained in the artery membranes. Significant deviation of 
Hill slopes from –1.0 was analyzed using the one-sample t-test, with p values less 
than 0.05 considered significant. 
 
3.2.7 Drugs and reagents 
125I-angiotensin IV (2200 Ci/mmol) and 125I-Sar1-Ile8-angiotensin II (2200 
Ci/mmol) were purchased from NEN Life Science Products, Boston, USA. All 
reagents and other peptides were purchased from Sigma Chemical Co, St Louis, 
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USA with the exception of Plummer’s inhibitor (Calbiochem- Novabiochem 
Corporation, California, USA). 
 
3.3  Results 
Competition binding experiments were performed to characterize the binding of 
various angiotensin ligands to the receptors mediating opposing vasodilator and 
vasoconstrictor response in the pulmonary trunk and artery respectively. 125I-Sar1-
Ile8-angiotensin II bound with similar high affinity to the trunk (Kd = 0.959 ± 0.609 
nM, Bmax = 0.34 ± 0.20 pmol/mg protein) and artery binding sites (Kd = 1.041 ± 
0.330 nM, Bmax = 0.71 ± 0.19 pmol/mg protein). There were no significant 
difference between the Kd and Bmax values obtained from the trunk and artery and 
they are consistent with those obtained in a previous ligand binding study in the 
rabbit pulmonary artery (Sim et al., 1998). 
 
Angiotensin peptides and antagonists displaced the binding of 125I-Sar1-Ile8-
angiotensin II to trunk and artery membranes of the rabbit pulmonary artery with 
the following rank order affinity:  Sar1-Ile8-angiotensin II > losartan > angiotensin 
II > angiotensin III > des-Asp-angiotensin I > angiotensin IV (Figure 3.1). PD 
123319 and divalinal-angiotensin IV were only able to show some displacement at 
concentrations higher than 10-4 M, indicating that AT1 but not AT2 and AT4 
receptors were probably present in the pulmonary trunk and artery. The Ki values of 






























































Figure 3.1 125I-Sar1-Ile8-angiotensin II competition curves in the rabbit 
pulmonary trunk and artery. 10 µg of membrane protein was incubated with 
0.02 nM radioligand at 15oC for 60 minutes. Each point represents the mean of 
3 experiments performed in duplicate. 
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different, highlighting similar structural requirements of the 125I-Sar1-Ile8-
angiotensin II binding sites in the trunk and artery (Table 1).  
 
To test the presence of more than one angiotensin receptor subtype within either the 
trunk or the artery, a comparison of fit for a one- and two-site model was done 
using the F-test. All competition curves fit the one-site model significantly better 
than the two-site   model (see r2 values in Table 1), suggesting that only one 
angiotensin binding site is present in both the trunk and artery. The corresponding 
Hill slopes were not significantly different from –1.0, except competition curves 
using Sar1-Ile8-angiotensin II and losartan in the trunk, further indicating no 
cooperativity and suggestive of a single class of binding site. 
 
In contrast to 125I-Sar1-Ile8-angiotensin II binding, 125I-angiotensin IV bound with a 
250-fold lower affinity to the 125I-angiotensin IV binding sites in the trunk (Kd = 
251.97 ± 84.34 nM, Bmax = 14.25 ± 1.64 pmol/mg protein) and artery (Kd = 254.47 
± 42.36 nM, Bmax = 15.37 ± 1.81 pmol/mg protein). There were no significant 
difference between the Kd and Bmax values from the trunk and artery. However, the 
receptor number for the 125I-angiotensin IV binding site was significantly higher 
than for the 125I-Sar1-Ile8-angiotensin II binding site (Bmax ≈ 0.5 pmol/mg protein) 





 125I-Sar1-Ile8-Angiotensin II Competition Binding Curves 
 
Radioligand - tissue Competing 
Ligand 





Sar1-Ile8-AngII 9.47 x 10-10 ± 5.89 x 10-10 0.923 ± 0.029 -0.798 ± 
0.021*
 Losartan 4.52 x 10-10 ± 7.35 x 10-10 0.909 ± 0.046 -0.789 ± 
0.022*
 AngII 2.52 x 10-8 ± 1.60 x 10-9 0.957 ± 0.015 -1.049 ± 0.117 
 AngIII 1.45 x 10-7 ± 6.69 x 10-8  0.948 ± 0.027 -1.051 ± 0.116 
 AngI(2-10) 2.39 x 10-6 ± 3.88 x 10-7 0.974 ± 0.006 -0.906 ± 0.040 
 AngIV 7.94 x 10-5 ± 2.44 x 10-5 0.944 ± 0.011 -0.892 ± 0.044 
 PD 123319 > 10-4 - - 
 Divalinal-AngIV > 10-4 - - 
     
125I-Sar1-Ile8-AngII  
- artery 
Sar1-Ile8-AngII 1.04 x 10-9 ± 3.23 x 10-10 0.960 ± 0.007 -1.141 ± 0.053 
 Losartan 3.11 x 10-8 ± 2.61 x 10-8 0.949 ± 0.006 -0.929 ± 0.154 
 AngII 3.36 x 10-8 ± 6.36 x 10-9 0.957 ± 0.020 -1.084 ± 0.115 
 AngIII 1.35 x 10-7 ± 4.54 x 10-8 0.940 ± 0.015 -1.020 ± 0.110 
 Des-Asp-AngI 2.02 x 10-6 ± 2.62 x 10-7 0.985 ± 0.004 -1.016 ± 0.094 
 AngIV 7.66 x 10-5 ± 1.93 x 10-5 0.967 ± 0.000 -0.883 ± 0.057 
 PD 123319 > 10-4 - - 
 Divalinal-AngIV > 10-4 - - 
 
125I-Angiotensin IV Competition Binding Curves 
 
Radioligand - tissue Competing Ligand Ki (M) r2 for single 
site fit 
Hill slope 
125I-AngIV - trunk AngIV 2.41 x 10-7 ± 7.36 x 10-8  0.972 ± 0.007 -1.037 ± 0.003 
 Divalinal-AngIV 1.37 x 10-6 ± 1.97 x 10-7 0.935 ± 0.031 -1.311 ± 0.221 
 Des-Asp-AngI 6.63 x 10-6 ± 2.03 x 10-6  0.954 ± 0.015 -1.056 ± 0.072 
 AngIII 4.03 x 10-6 ± 5.94 x 10-7 0.916 ± 0.047 -1.054 ± 0.122 
 AngII 1.44 x 10-4 ± 8.52 x 10-5 0.803 ± 0.129 -1.360 ± 0.334 
 Losartan > 10-4 - - 
 PD123319 > 10-4 - - 
 Sar1-Ile8-AngII > 10-4 - - 
     
125I-AngIV - artery AngIV 2.51 x 10-7 ± 4.17 x 10-8 0.940 ± 0.026 -1.058 ± 0.024 
 Divalinal-AngIV 2.01 x 10-6 ± 5.04 x 10-7 0.952 ± 0.018 -1.011 ± 0.123 
 Des-Asp-AngI 7.39 x 10-6 ± 5.66 x 10-7 0.913 ± 0.032 -1.224 ± 0.141 
 AngIII 1.36 x 10-5 ± 5.72 x 10-6 0.906 ± 0.039 -1.026 ± 0.050 
 AngII 4.63 x 10-5 ± 7.93 x 10-6 0.850 ± 0.108 -1.056 ± 0.072 
 Losartan > 10-4 - - 
 PD123319 > 10-4 - - 
 Sar1-Ile8-AngII > 10-4 - - 
 
 
Table 1 Competition binding constants for 125I-Sar1-Ile8-angiotensin II 
and 125I-angiotensin IV binding to rabbit pulmonary trunk and artery 
membranes. Results are expressed as mean ± SEM; n = 3. *significantly 
different from –1.0. 
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Angiotensin peptides displaced the binding of 125I-angiotensin IV to trunk and 
artery membranes of the rabbit pulmonary artery with the following rank order 
affinity: angiotensin IV > divalinal-angiotensin IV > angiotensin III ≈ des-Asp-
angiotensin I > angiotensin II (Figure 3.2). The Ki values for losartan, PD 123319 
and Sar1- Ile8-angiotensin II were more than 10-4 M. The Ki values of the 
competition curves in the trunk were not significantly different from the artery. All 
competition curves fit the one-site model significantly better than the two-site 
model and the corresponding Hill slopes were not significantly different from –1.0 
(Table 1). 
 
3.4  Discussion 
The binding of 125I-Sar1-Ile8-angiotensin II to the trunk and artery membranes of the 
rabbit pulmonary artery was displaced by Sar1-Ile8-angiotensin II, losartan, 
angiotensin II, angiotensin III, des-Asp-angiotensin I and angiotensin IV. The Ki 
values correlated well with concentrations effective in either eliciting the 
vasodilator and vasoconstrictor response or the blocking of these responses (Sar1-
Ile8-angiotensin II, losartan) in organ bath experiments. This provides evidence that 
the 125I-Sar1-Ile8-angiotensin II binding site corresponds to the angiotensin receptors 
mediating the opposing vasodilator and vasoconstrictor response in the trunk and 
artery respectively. The ability of losartan and the inability of PD 123319 and 
divalinal-angiotensin IV to displace the radioligand, and the rank order affinity of 
the receptors for the competing angiotensin peptides indicate that the receptors are 
of   the AT1  subtype  (Touyz et al., 2000).   Correspondingly,  losartan  but  not  PD 
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Figure 3.2 125I-angiotensin IV competition curves in the rabbit pulmonary 
trunk and artery. 10 µg of membrane protein was incubated with 1 nM 
radioligand at 37oC for 120 minutes. Each point represents the mean of 3 
experiments performed in duplicate. 
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 123319 and divalinal-angiotensin IV blocked the vasoconstrictor and vasodilator 
response in organ bath experiments. 
 
The similar Ki values in the trunk and artery membranes suggest similar structural 
requirements for the functionally different receptors, and provide evidence against 
two receptor subtypes mediating the differential response.  A significantly better fit 
for a one-site model for all the competition curves also tends to eliminate the 
possibility that within either the trunk or the artery, the response seen is a composite 
result of more than one receptor subtype, which could have contributed to the 
differential response observed.  
 
Competition binding experiments were repeated using 125I-angiotensin IV because 
functional studies (chapter 2) indicate that angiotensin IV may have selectivity for 
the receptor mediating vasodilation in the pulmonary trunk. Equilibrium 
dissociation constants from homologous competition binding demonstrated large 
differences in Bmax for the 125I-Sar1-Ile8-angiotensin II (approximate range: 0.1 to 
0.9 pmol/mg protein) and 125I-angiotensin IV binding site (approximate range: 12 to 
17 pmol/mg protein), which suggested that the radioligands bound to distinct 
binding sites. The site defined by 125I-angiotensin IV bound with the following rank 
order affinity to angiotensin IV > divalinal-angiotensin IV > angiotensin III ≈ des-
Asp-angiotensin I > angiotensin II, but were unable to bind to losartan, PD 123319 
or Sar1-Ile8-angiotensin II. This pattern of binding correlated poorly with functional 
responses in organ bath experiments and seems consistent with an AT4 binding site 
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(Swanson et al., 1992). However, the Kd of angiotensin IV for the 125I-angiotensin 
IV binding site (approximate range: 167.63 to 296.83 nM) is much higher than what 
is generally reported for the AT4 receptor (Kd ≈ 1 nM) (Wright et al., 1995). Table 2 
provides the binding constants for AT4 receptors located in several peripheral 
tissues in   various species   (de Gasparo et al., 2000).   The   discrepancy in Bmax, 
the poor correlation of the Ki values with potencies producing a functional response 
and the inability of Sar1-Ile8-angiotensin II and losartan to displace 125I-angiotensin 
IV binding suggest that 125I-angiotensin IV did not bind to the pharmacological site 
of interest. 
 
No explanation was forthcoming for the inability of 125I-angiotensin IV to bind to 
the angiotensin receptor of interest since angiotensin IV at 10 µM was able to elicit 
a vasodilator response in the trunk of the rabbit pulmonary artery. Perhaps the 
inclusion of the 125I moiety caused significant changes in conformation of 
angiotensin IV such that the peptide was unable to fit into the ligand binding site of 
the receptor.  However, we were unable to explore this possibility as alternative 
forms of radiolabeling angiotensin IV e.g. using 3H or 14C, which does not require 
the inclusion of a foreign molecule, were not commercially available. 
 
Taken together, the present findings support the observations that the angiotensin 
receptors mediating the differential vasoconstrictor and vasodilator responses in the 
artery and trunk of the rabbit pulmonary artery respectively are of the AT1 subtypes. 
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 α Mean ± S.D., n = 2-4. Study performed with 125I-angiotensin IV. 
Species Tissue Kd (nM) Bmax (pmol/mg 
protein) 
    
Rabbit Heart 1.75 ± a5α 0.731 ± 0.163 
Rat Heart 3.3 ± 1.1 0.320 ± 0.066 
Bovine Adrenals 0.74 ± 0.14 3.82 ± 1.12 
Guinea Pig Heart 1.33 ± 0.02 0.144 ± 0.019 
Guinea Pig Hippocampus 1.29 ± 0.18 0.499 ± 0.062 
Bovine Vascular smooth 
muscle 
1.85 ± 0.45 0.960 ± 0.100 
Bovine Vascular smooth 
muscle 
0.70 ± 1.0 0.476 ± 0.057 
Guinea Pig Vascular smooth 
muscle 
0.40 ± 0.09 1.040 ± 0.239 
Monkey Kidney 1.5 ± 0.31 1.000 ± 0.212 
Guinea Pig Colon 0.84 ± 0.08 0.659 ± 0.075 
Human Prostate 0.60 ± 0.15 1.399 ± 0.152 
 
Table 2 Binding constants for AT4 receptors in various species and 
tissues (adapted from Gasparo et al, 2000) 
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It further demonstrated that the angiotensin receptors in the trunk and artery shared 
similar structural requirements for its ligands, suggesting that it is unlikely that 
different angiotensin receptor subtypes mediated the opposing responses. Neither 
were different composites of receptor types likely to be responsible for the 
differential responses since the findings determined a single binding site for both 
the trunk and artery of the rabbit pulmonary artery.  
 
From the present results, it is difficult to define the mechanism of the opposing 
vasoconstrictor and vasodilator response reported in the previous chapter. We 
discounted vasodilator response mediated by the AT4 receptor since the binding 
profile of 125I-angiotensin IV corresponded poorly with functional responses. 
Furthermore, divalinal-angiotensin IV did not block the vasodilator response. 
However, we cannot exclude the possibility of further angiotensin receptors that 
are, as yet, uncharacterized and undistinguishable by Sar1-Ile8-angiotensin II and 
losartan, including the existence of mRNA splice variants of the AT1 receptor that 
could have contributed to the differential responses. Therefore, we next proceeded 
to further characterize the angiotensin receptors in the pulmonary trunk and artery 







The actions of angiotensin II are mediated by two pharmacologically characterized 
classes of angiotensin receptors, AT1 and AT2 (de Gasparo et al., 2000). While the 
physiological role and the intracellular signaling pathways of the AT2 receptor are 
not clearly defined, the angiotensin AT1 receptors have been extensively studied 
and shown to mediate virtually all of the known physiological actions of 
angiotensin II in cardiovascular, renal, neuronal, endocrine, hepatic and other target 
cells (de Gasparo et al., 2000). Genome analysis and homology cloning 
demonstrated that the rat and mouse AT1 receptors exist as two distinct subtypes, 
termed AT1A and AT1B, which are encoded by two different genes (Iwai and 
Inagami, 1992) They have approximately 95% identity in their amino acid 
sequences and are also similar in terms of their ligand binding and activation 
properties but differ in their tissue distribution, chromosomal localization, genomic 
structure, and transcriptional regulation (Iwai and Inagami, 1992). This suggests 
that they could mediate different physiological function. None of the other cloned 
mammalian AT1 receptors, including those from the cow (Sasaki et al., 1991), 
human (Bergsma et al., 1992; Curnow et al., 1992), pig (Itazaki et al., 1993), rabbit 
(Burns et al., 1993), and dog (Burns et al., 1994) appear to have subtypes. Southern 
hybridization analysis of at least eight different restriction enzyme fragments of the 
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rabbit genomic DNA using rabbit AT1 cDNA as a probe did not produce evidence 
for a subtype of the AT1 receptor (Burns et al., 1993). 
 
The existence of two distinct angiotensin AT1 receptor subtypes differentially 
distributed in the rabbit pulmonary trunk and artery is suggested by differential 
response between the pulmonary trunk and artery to angiotensin peptides. Although 
Southern analysis indicates that a single gene encodes one AT1 receptor in the 
rabbit (Burns et al., 1993), the possibility that AT1 receptor splice variants in the 
rabbit could account for the differences in response cannot be ruled out. The 
purpose of the present study was therefore to further characterize the angiotensin 
receptors in the rabbit pulmonary trunk and artery and to determine if different 
subtypes of the AT1 receptor, including splice variants, exist in the rabbit using 
Northern blot analysis. 
 
4.2 Rationale for Experimental Design 
In contrast to reports of two angiotensin AT1 receptor subtypes being identified in 
rodents (AT1A and AT1B), only a single AT1 receptor subtype has been reported in 
the rabbit. In our experimental strategy to determine if more than one AT1 receptor 
subtype exists in the rabbit, we generated two probes from published rabbit cDNA 
sequence (Burns et al., 1993) (see Figure 4.1), one from the coding region (hereafter 
known as the coding probe) and the other from the non-coding region (hereafter 
known as the non-coding probe), for hybridization in subsequent Northern blots. 







1    gatttgaaat atctagatta ttctaaaatg gctgggtttt tatctgaata agtcaaagaa 
61   gccatccagg aagtcaacat cagctgcgtt tgatgagaca aattcaaccc aggccatcaa 
121  aatgatgctc aactcttcta ccgaagatgg tatcaaaaga atccaggatg actgtcccaa 
181  agctggaagg cacaattaca tatttgtcat gattcctact ctgtatagca tcatctttgt 
241  ggtgggaata tttgggaaca gcttggcggt gattgtcatt tacttttaca tgaaactcaa 
301  gactgtggcc agtgtttttc ttttgaattt agcattggct gacttatgct ttttactgac 
361  tttgccactc tgggctgtct acactgctat ggaataccgc tggccctttg gcaattacct 
421  gtgtaagatt gcttcggcca gtgtcagttt caacctctat gccagtgtat ttctactcac 
481  gtgtctcagc attgaccgct acctggctat tgtccacccg atgaagtctc gccttcgacg 
541  cacaatgctt gtagccaaag tcacctgcat cattatttgg ctgctggctg gcttggccag 
601  tttaccagct atcatccacc gaaacgtatt tttcatcgag aacaccaaca tcacggtttg 
661  tgctttccat tacgagtccc aaaactcaac cctccccata gggctaggcc tgaccaaaaa 
721  tatactgggc ttcctatttc cctttctgat cattcttaca agctacactc ttatttggaa 
781  ggccctcaag aaggcttacg agattcagaa gaacaagcca agaaatgatg atatttttaa 
841  gatcattatg gcaattgtgc ttttcttttt cttctcctgg gttccccacc aaatattcac 
901  tttcctggat gtgttgattc agctgggggt cattcacgac tgcagaatcg cagatatcgt 
961  ggacactgcc atgcccatca ccatctgcat agcttatttt aacaactgcc tgaatcccct
1021 tttttatggc tttctgggga aaaaatttaa gaaatatttt ctccagcttc ttaaatatat 
1081 tcccccgaaa gccaaatccc attcaaatct atcaacaaag atgagcacgc tctcctaccg 
1141 cccctcagat aacgtgagct catcctccaa gaagcccgtg ccctgctttg aggttgagtg 
1201 acatgttcaa aacctgttgg tgaagcaact ttgtcaaaga aggagccaaa gaaacattcc 
1261 tgcacagcac tgcgctacca aatgagcatt agctactttt caggatgtaa ggagaagttg 
1321 gatcaattgg actgaaccgc cggcttgtct acagctcgaa caaaagcttt ccttttcttt 
1381 agcaacaaaa caaagcagag ccacattttg cattaaatac aagatggctg ctcaaagaat 
1441 gatgacagaa actggacaaa tgtgttgatt tcagaaattt tgctggcgga aatgcagtct 
1501 cgccagtctt ctcttgttct attatttttg atttctatat aaaggtattt agaggaagtg 
1561 aaatctacag agcagcaaca ggagatcaca gttcaggatt gttctttctg cccaatttcc 
1621 aaggggcgat gaagctttta tgcctgttta gccattagca gctgtgacca cttgtacctg 
1681 ctccaatgca tttcgtgcaa aaatgtgcta agcagtagtt gtcaagtttc agaacctttt 
1741 atgaaattca accagagtca taaagattca cactgccaaa ataatggtgg cagaatggct 
1801 tcttgcaaaa tggtgttact aaagttacgt gtaagagtta aatactagca aaggtgtcac 
1861 tctagtccca gggagttgtg ttctcctggt catattagtc ttatttcata tctgataact 
1921 gtatatagtt tatagtaaaa agattatata tcgtaaagta tgccaagctg tttcaacaaa 
1981 gtatatattt tacatacaca tctacatgta tcaatgtcgt taaactgttg ttacttgatt
2041 caaatctagc aaagctctat ttaccttaaa taaaataatt gtaggaatt 
 
 
Figure 4.1 Nucleotide sequence of cDNA encoding a rabbit kidney cortex 
angiotensin II receptor. The open reading frame is the nucleotide sequence in 
bold and consists of nucleotides encoding 359 amino acids. The underlined 
sequence represents the upstream and downstream reverse primers used to 
generate the coding and non-coding probes, respectively, for Northern blot 
analysis of total RNA isolated from the rabbit pulmonary trunk and artery.  
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within the coding regions of the rat AT1A and AT1B cDNAs, but marked differences 
in the non-coding regions. We made the assumption that if AT1 receptor subtypes 
exist in the rabbit, they would similarly share a high sequence homology in the 
coding region and a low sequence homology in the non-coding region of the rabbit 
AT1 receptor sequence. The coding probe would thus hybridise to the coding 
regions of all putative rabbit AT1 subtype mRNAs in a Northern blot while the non-
coding probe would only be able to selectively bind to the non-coding region of the 
published AT1 subtype mRNA but not other putative AT1 subtypes. The presence of 
additional bands in a Northern blot of total RNA isolated from rabbit pulmonary 
vasculature using the coding probe, that are not observed in a similar Northern blot 
using the non-coding probe, would indicate the presence of more than one rabbit 
AT1 receptor subtypes. 
 
4.3 Materials and Methods 
4.3.1 Isolation of primary vascular smooth muscle cells (VSMCs) – primary 
explant technique 
A male albino rabbit weighing 1.5 - 2.5 kg was killed by cervical dislocation or 
carbon dioxide poisoning. The thorax area was disinfected with 70% ethanol and 
the thorax opened by cutting longitudinally along the median line with sterile 
scissors and forceps, ensuring sterility throughout the procedure. The heart was 
removed and transferred to a petri dish containing cold phosphate-buffered saline 
(PBS). The pulmonary trunk and artery were located with the aid of a sterile 1 ml 
pipette and connective and fatty tissue was removed. 
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 The isolated pulmonary trunk and artery was transferred to fresh PBS and cut into 
two pieces: the trunk and artery. Each vessel was then cut open. With the 
endothelium side face up, endothelial cells were gently removed by scrapping the 
luminal surface with the blunt end of a surgical blade. The luminal surface was 
intensely rinsed with PBS. 
 
Using two fine forceps, one having a curved tip, the medial layer was stripped off 
from the adventitia. The adventitia was grasped at the lateral margin with a straight 
forceps and the medial layer was carefully detached from the adventitia with the 
curved forceps. The medial layer obtained was then transferred to culture medium 
(DMEM/F12 1:1, pH 7.4) and cut into approximately 0.1 cm2 media explants with 
surgical blades. The media explants were transferred to 6-well plates containing 
small volumes of medium just covering the explants. The explants were incubated 
in a 37oC humidified incubator with an atmosphere of 95% air and 5% CO2. The 
medium was changed every 48 hours.  
 
4.3.2 Cell culture 
Between day 3 and day 5 after the isolation of media explants, smooth muscle cells 
(SMCs) started to migrate out from the explants. After 14-21 days the plastic 
bottom was covered with SMCs. To passage the cells, the media explants were 
removed using fine forceps. The primary SMCs were trypsinized using 
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trypsin/EDTA and counted using the coulter counter. The SMCs were routinely 
seeded at a density of 10,000 cells/cm2 and cultured in 75 cm2 flasks. 
 
To determine that no other cell type (fibroblasts or endothelial cells) had 
contaminated the SMC cultures, the SMCs were identified morphologically 
(spindle-shaped apperance) and by their growth pattern (characteristic “hill and 
valley” growth pattern) with a light microscope as well as characterized by 
immunological staining of the cytoskeleton protein, alpha-smooth muscle actin, 
using flow cytometry. 
 
4.3.3 Isolation and purification of RNA 
Total RNA was isolated from rabbit pulmonary trunk and artery VSMCs using a 
total RNA isolation system (Promega RNAgents® Total RNA Isolation System). 
Approximately two 75 cm2 culture flasks per cell type (trunk or artery) of confluent 
cells containing a total of about 5 x 106 cells were used for each RNA isolation. The 
isolation of RNA was carried out in a designated ribonuclease-free environment 
using sterile disposables, ribonuclease (RNase)-free glassware and sterile 
techniques. 
 
Confluent cells were washed with phosphate-buffered saline (PBS), trypsinized and 
pelleted at 4oC. The pelleted cells were washed with culture medium containing 
serum, pelleted and cell membranes disrupted by mixing thoroughly with pre-
chilled denaturing solution (55% guanidine thiocyanate, 45% citrate/sarcosine/β-
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mercaptoethanol (CBS) buffer) to denature nucleoprotein complexes, release RNA 
and inactivate intracellular ribonuclease (RNase). Contaminating DNA and proteins 
were removed by adding sodium acetate followed by phenol:chloroform:isoamyl 
alcohol (125:24:1) (acid extraction) and mixed by inversion; DNA and proteins 
partitioned into the organic phase while the RNA partitioned selectively into the 
aqueous phase. After the phases were separated by centrifugation, the top aqueous 
phase was removed and RNA precipitated by adding isopropanol. The RNA was 
pelleted by centrifugation, washed with 70% ethanol to remove salt, air dried and 
dissolved in nuclease-free water. 
 
The yield (µg/µl) and purity of RNA were determined spectrophotometrically at 
260 and 280 nm, where 1 absorbance unit (A260) ~ 40 µg of single-stranded 
RNA/ml (precise = 44.19 µg RNA/ml) and pure RNA has a A260/A280 ratio of 2.0 ± 
0.05 (acceptable range: 1.7 – 2.0). The integrity of isolated RNA was determined by 
denaturing agarose gel electrophoresis using formaldehyde as the denaturing agent. 
Only samples which show a 2:1 ratio of 28S to 18S eukaryotic ribosomal RNA by 
ethidium bromide staining were used in subsequent experiments.  
 
For RNA preparations used for the generation of probes, the total RNA samples 
were treated with DNA polymerase (DNase) to remove trace amounts of 
contaminating genomic DNA. Removal of DNA is important because amplification 
products will be generated from subsequent reverse transcriptase-polymerase chain 
reaction (RT-PCR) if any trace DNA is present. 
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 4.3.4 Generation of probes for Northern blot 
4.3.4.1  Primers 
The primers derived from the coding region of the published rabbit cDNA sequence 
(Figure 4.1) for synthesizing the coding probe were 1) upstream primer, 5’ 
ATCAAAAGAATCCAGGATGAC 3’ and 2) downstream reverse primer, 5’ 
AAAAAAGGGGATTCAGGCAGTT 3’. The primers derived from the non-coding 
region for synthesizing the non-coding probe were 1) upstream primer, 5’ 
AAAGAAGGATCCAAAGAAACA 3’ and 2) downstream reverse primer, 5’ 
AGAGCTTTTCTAGATTTGAAT 3’. 
 
All primers were synthesized by the National University Medical Institutes, 
Singapore. 
 
4.3.4.2  RT-PCR and DNA cloning 
Reverse transcription and amplification of the coding and non-coding probes were 
carried out using the Access RT-PCR System (Promega). The reaction mix was 
prepared by combining specified volumes of the previously isolated total RNA, 
upstream and downstream primers, dNTP mix, magnesium sulphate, reverse 
transcriptase, DNA polymerase in reaction buffer on ice, using nuclease-free water 
to make up to a total volume of 50 µl. The reaction was initiated by adding the 
RNA template (total RNA). The reaction was overlayed with 2 drops of mineral oil 
to prevent condensation and evaporation. The reaction tubes were incubated at 48oC 
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for 45 minutes to allow synthesis of first-strand cDNA by reverse transcriptase 
reaction, followed by incubation at 94oC for 2 minutes to denature the RNA/cDNA 
hybrid. Denaturing, annealing of upstream and downstream primers, and extension 
were then carried out for 40 cycles of 94oC for 30 s, 60oC for 1 minute and 68oC for 
2 minutes, respectively. A final 7 minute extension at 68oC was allowed after the 
final cycle.  
 
The PCR products obtained were separated by agarose gel electrophoresis and 
identified by UV transillumination of an ethidium-stained gel. The following PCR 
products were obtained: 1) coding probe – 0.8 kb fragment; 2) non-coding probe – 
0.8 kb fragment. Following isolation of the coding and non-coding probes using 
low melting point agarose gels, the gel slices containing the two DNA probes were 
removed from the gel, melted at 70oC for 30 minutes and subjected to phenol 
extraction and ethanol precipitation. The coding and non-coding DNA probes 
obtained were washed with ethanol and reconstituted in water. 
 
The coding and non-coding DNA probes were inserted into the pBluescript SK (+) 
(pKS) plasmid by restriction digestion (coding: BamHI, EcoRI; non-coding: 
BamHI, XBaI) and ligation. E. Coli cells were grown to an OD590 of 0.4, 
concentrated by centrifugation and resuspended in ice-cold calcium chloride to 
make the cells competent. Ligation products were added to competent E. Coli cells, 
heat-shocked at 45oC for 1.5 minutes and cultured at 37oC in a shaking water bath 
for 45 minutes. Single inoculums of cells were then streaked across agar plates to 
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isolate single colonies of transformed cells and incubated at 37oC until colonies 
became visible. 
 
Single colonies of E. Coli cells were cultured overnight in LB medium containing 
ampicillin in a 37oC shaking water bath and cells concentrated by centrifugation. 
The cells were lysed by resuspension in STET solution (8% sucrose, 5% Triton X-
100, 50 mM EDTA and 50 mM Tris.Cl, pH 8.0) followed by immersion in a 100oC 
water bath for 1 to 2 minutes and centrifugation. Plasmid DNA in the supernatant 
was precipitated with isopropanol, centrifuged and the plasmid DNA pellet washed 
with ethanol and resuspended in water. The plasmid DNA was identified by 
selective restriction digestion and subsequent agarose gel electrophoresis, as well as 
base sequencing to ensure that the correct coding and non-coding probes were 
obtained. The plasmid DNA was restriction digested, the coding and non-coding 
probes isolated by low melting point agarose gel electrophoresis and subjected to 
phenol extraction and ethanol precipitation as described previously. The sizes of 
both coding and non-coding probes were 0.8 kb. 
 
4.3.5 Northern Blot 
For Northern blot analysis, 20 µg of total RNA, isolated as previously described in 
Section 2.4.3, was separated by 1.0 % agarose-formaldehyde gel electrophoresis 
and transferred onto nylon membranes overnight. The coding and non-coding 
probes were labeled with [32P]-dCTP using the Klenow fragment of DNA 
polymerase I by the random primer method (Prime-a-Gene Labeling System, 
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Promega). Pre-hybridisation was performed at 68oC for 2 hours in a solution of 6X 
SSC (1X SSC = 0.2 M NaCl and 0.3 M sodium citrate, pH 7.0), 5X Denhardt’s, 
0.5% sodium dodecyl sulfate (SDS) and 100 µg/ml of salmon sperm DNA. 
Hybridisation was performed overnight at 68oC in a solution of 6X SSC, 0.5% SDS 
and [32P]-dCTP-labeled probe. The membranes were washed 4 times in 1X SSC and 
0.1% SDS at 38oC for 10 minutes each, then 2 times in 0.2X SSC and 0.1% SDS at 




Total RNA was extracted from rabbit pulmonary trunk and artery. Representative 
autoradiograms derived from a Northern blot analysis are shown (Figure 4.2). Both 
the coding and non-coding probe hybridized to a single band in a Northern blot of 
total RNA from the rabbit pulmonary trunk and artery, suggesting that with 
reasonable probability the rabbit pulmonary trunk and artery express a single AT1 
receptor subtype.  
 
4.5 Discussion 
Differential vasoconstrictor and vasodilator response to angiotensin II, angiotensin 
III and angiotensin IV suggest two distinct angiotensin AT1 receptor subtypes exist 
differentially distributed in the rabbit pulmonary trunk and artery. To determine if 
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 blot analysis of total RNA isolated from the rabbit pulmonary trunk and artery was 
carried out using two probes generated from the coding and non-coding regions of 
published rabbit AT1 cDNA sequence (Burns et al., 1993). Based on what was 
similarly observed for AT1A and AT1B receptor subtypes in the rat, the coding 
regions of possible rabbit AT1 receptor subtypes were assumed to share a high 
sequence homology while the non-coding regions share a low sequence homology. 
The presence of additional bands in a Northern blot using the coding probe 
(generated from the coding region of the rabbit AT1 published cDNA sequence) 
when compared to a similar Northern blot using the non-coding probe (generated 
from the non-coding region) would indicate the presence of more than one AT1 
receptor subtype in the rabbit. In our present findings, both the coding and non-
coding probe hybridized to a single band in a Northern blot of total RNA isolated 
from rabbit pulmonary trunk and artery, suggesting with reasonable probability the 
presence of a single AT1 receptor subtype in the pulmonary vasculature. This 
finding confirms our previous findings from receptor binding studies which also 
indicate a single class of AT1 receptors in the pulmonary vasculature. It is also 
consistent with similar previous reports that the rabbit contains only a single AT1 
receptor subtype, in contrast to rodents (Burns et al., 1993).  
 
Although both Southern blot analysis carried out by Burns and colleagues (1993) 
and Northern blot analysis in our laboratory have suggested the presence of a single 
AT1 receptor in the rabbit pulmonary trunk and artery, the possibility that other AT1 
receptor subtypes exist cannot be ruled out for several reasons. Firstly, the 
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experimental strategies for both Southern and Northern blot analysis require that the 
AT1 receptor subtypes share significant homology with the AT1 receptor sequence 
used to generate the probe to allow detection. In addition, the lengths of mRNAs of 
AT1 receptor subtypes must differ such that they can be visualized as distinct bands 
on a Northern blot when hybridized with a complementary radioactive probe. 
Hence, AT1 receptor subtypes with significant differences in sequence with the 
published AT1 receptor sequence or those with similar mRNA lengths would not be 
detected by these experimental strategies.   
 
The present findings suggest that the rabbit pulmonary trunk and artery contain a 
single AT1 receptor subtype and that this receptor is responsible for the differential 
responses observed in the rabbit pulmonary trunk and artery. These findings raise 
the question of how a single AT1 receptor subtype is regulated to mediate opposing 
vasoconstrictor and vasodilator responses in different segments of the short rabbit 
pulmonary artery. Rowe and Dixon (2000) recently reported that intravenous bolus 
administration of angiotensin II, angiotensin III and angiotensin IV produced a 
pressor peak followed by a depressor phase in the arterial blood pressure in the 
rabbit, with angiotensin III being a more potent depressor than angiotensin II and 
angiotensin IV being 100-fold less potent than angiotensin III. Both angiotensin III-
induced pressor and depressor components were blocked by losartan but not by 
PD123319, suggesting that both pressor and depressor actions were AT1-mediated 
effects. Unlike other members of the G-protein coupled receptor superfamily in 
which a specific receptor subtype is usually coupled to a specific effector, AT1 
 91
receptors are coupled to multiple, distinct signal transduction processes, leading to 
diverse biological actions even within a single cell type i.e. the vascular smooth 
muscle cell (Touyz et al., 2000). The signaling processes are highly complex and 
multiphasic with distinct temporal characteristics. Angiotensin II is known to 
induce phospholipase C (PLC) phosphorylation (leading to formation of IP3 and 
DAG) and Src activation within seconds, phospholipase A2 (PLA2), phospholipase 
D (PLD), tyrosine kinase and mitogen-activated protein kinase (MAPK) activation 
within minutes, and proto-oncogene expression and protein synthesis within hours.  
 
Our present data suggests that the AT1 receptor present in the pulmonary trunk and 
artery may be identical yet mediate a distinct and opposite biological response. The 
subsequent receptor-coupled signal transduction cascade may confirm such 
differences in the receptor role. As the vasodilator response of the rabbit pulmonary 
trunk to angiotensin III, angiotensin IV and des-Asp-angiotensin I is blocked by 
indomethacin, angiotensin-induced production of vasodilator prostaglandins (PGE2 
and/or PGI2) is implicated in its signal transduction pathway. In our next study, we 
investigated the angiotensin-induced prostaglandin release as well as the inositol 
triphosphate signaling pathways in cultured VSMCs from the trunk and artery of 
the rabbit pulmonary artery.  
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CHAPTER 5 
SIGNAL TRANSDUCTION STUDIES 
 
5.1 Introduction 
We reported earlier the differential responses of the rabbit pulmonary trunk and 
artery to angiotensin II, angiotensin III and angiotensin IV, with both contractile 
and relaxant responses mediated by a single AT1 receptor. The next logical question 
to ask was, “What intracellular processes mediate these contradictory responses.” 
Hence, an attempt was made to elucidate the signal transduction mechanisms that 
may mediate these opposing responses. 
 
One of the earliest events in VSMCs following angiotensin II stimulation is the 
activation of phospholipase C (PLC) through the heterotrimeric Gq protein, which 
results in the rapid hydrolysis of phosphatidylinositol 4,5-bisphosphate to inositol 
1,4,5-triphosphate (IP3) and diacylglycerol (DAG) (Griendling et al., 1989). As a 
result, IP3 levels increase albeit transiently due to its rapid metabolism, often 
returning towards basal levels within 15 – 30 seconds (Minami et al., 1991; 
Wojcikiewicz et al., 1993).  IP3 interacts with IP3 receptors to release calcium from 
intracellular stores. Consequently, the transient increase in IP3 is correlated with an 
initial increase in cytosolic Ca2+ and the phasic component of vascular smooth 
muscle contraction.  
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In addition to the activation of PLC, angiotensin II has been shown to 
simultaneously activate phospholipase A2 in vascular smooth muscle (Kubalak et 
al., 1993). PLA2 activation leads to the release of arachidonic acid, which is 
thereafter metabolized into prostaglandins. An increase in prostaglandin release, 
mainly PGI2 and PGE2, in response to angiotensin II has been described in VSMCs 
(McGiff, 1981; Nasjletti et al., 1982; Lang and Vallotton, 1989; Jaiswal et al., 
1993). PGI2 activates adenylyl cyclase and increase adenosine 3’,5’-cyclic 
monophosphate (cAMP) to relax vascular smooth muscle (Bolton, 1979). This 
vasorelaxation may modulate angiotensin II-induced contraction, thus buffering the 
effect of vasoconstriction (Jackson and Herzer, 1993). Consequently, the vascular 
smooth muscle tone is controlled by a balance between the cellular signaling 
pathways that mediate the generation of force (contraction) and the release of force 
(relaxation). 
 
In endothelium denuded noradrenaline pre-contracted rabbit pulmonary vessels, 
angiotensin II elicited a further contractile response in both the trunk and the artery. 
Angiotensin III similarly elicited a further contractile response in the artery but 
relaxed the pre-contracted trunk. Angiotensin IV caused no changes in the vascular 
tone in the artery and relaxed the pre-contracted trunk. These angiotensin responses 
were all found to be blocked by losartan (selective AT1 receptor antagonist), but not 
PD123319 (selective AT2 receptor antagonist). In addition, indomethacin blocked 
the angiotensin III- and angiotensin IV-mediated relaxant response in the trunk, 
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suggesting that the vasorelaxation was probably mediated by the release of 
prostaglandins like PGE2 and PGI2.  
 
To elucidate the signaling mechanisms involved in these differential responses, we 
first compared the release of PGE2 and PGI2 from both rabbit pulmonary trunk and 
artery VSMCs when stimulated with angiotensin II, angiotensin III and angiotensin 
IV. Next, we measured the inositol (1,4,5)-triphosphate (IP3) mass content in 
angiotensin II- and angiotensin IV-stimulated rabbit pulmonary trunk  tissue slices. 
 
5.2 Rationale for experimental design 
5.2.1 Prostaglandin studies 
Primary cultures of rabbit pulmonary trunk (PTSMCs) and artery smooth muscle 
cells (PASMCs) were used for measuring prostaglandin release because the use of 
SMC culture is well established and convenient for measurement of signal 
transduction modalities. Culture systems have several advantages, including 
obtaining a pure smooth muscle population devoid of endothelial, adventitial and 
other cell contamination, enabling signal transduction investigations to be solely 
attributed to smooth muscle cells. 
 
PGE2 and PGI2 are the major vasodilator prostaglandins produced in the vasculature 
(Hassid and Williams, 1983; Schror, 1993). This governed our choice of 
prostaglandins to measure from the rabbit pulmonary trunk and artery. 
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5.2.2 Inositol triphosphate studies 
Determinations of IP3 have been mainly indirect, relying on the loading of tissue or 
cells with myo-2-[3H]inositol ([3H]inositol), which incorporates to 
phosphotidylinositol 4,5-biphosphate (PIP2). PIP2 is broken down to IP3 on receptor 
stimulation. The IP3 isomers thus obtained are subsequently separated and 
quantitated by HPLC. The disadvantages of such procedures are: (1) the assumption 
that all pools of inositol phosphates have been labeled to equilibrium is rarely 
established, and (2) agonist-induced changes in the specific radioactivity of inositol 
triphophates are sometimes inevitable. In addition, such techniques are laborious 
and time-consuming. Hence, although the method is not as widely adopted, we 
chose a mass measurement method using a radioreceptor assay (Challiss et al., 
1988), which allows the estimation of the ‘active’ calcium-mobilizing isomer (IP3) 
of the inositol phosphates. This method takes advantage of the presence of 
saturable, high-affinity binding sites for IP3 in microsomal fractions of bovine 
adrenal cortex or rat cerebellum (Challiss et al., 1988; Bredt et al., 1989; Palmer et 
al., 1989; Nibbering et al., 1990). 
 
In this study, only IP3 production stimulated by angiotensin II and angiotensin IV in 
the pulmonary trunk was measured. The angiotensin III-mediated stimulation of IP3 
production was not measured since isolated tissue experiments suggest that its 
actions are mediated by a break down product, likely angiotensin IV. Because the 
differential vasoconstrictor and vasodilator response was observed in the trunk but 
not in the artery, only trunk tissue slices were used. 
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 Endothelium-denuded rabbit pulmonary trunk tissue slices were used instead of 
cultured VSMCs (VSMCs) for measurement of IP3 release for several reasons. We 
encountered several technical difficulties in the use of pulmonary trunk and artery 
VSMCs for the PG assays. Firstly, approximately 5 passages of the primary VSMC 
culture were required to obtain sufficient number of cells to be assayed because of 
the low proliferative capability of the primary VSMC culture. Hence, VSMCs from 
passage 5 to 12 were used in the PG assays. High variability in the PG assay results 
was also observed which may be related to the phenotypic modulation of VSMCs in 
culture for many passages (Chamley-Campbell et al., 1979; McMurray et al., 1991; 
Birukov et al., 1993). In an attempt to address these difficulties, we used pulmonary 
trunk and artery tissue slices instead of VSMCs in our IP3 assay. In addition to 
avoiding phenotypic modulation of VSMCs in the intact tissue, tissue slices allow 
ready tissue handling and retain some degree of structural integrity. VSMCs also 
remain in close proximity with the extracellular matrix and other tissue, thus 
contributing to the maintenance of a high degree of functional integrity relative to 
the in vivo situation.  
 
5.3 Materials and Methods  
5.3.1  Prostaglandin studies 
5.3.1.1  Cell culture 
Primary cultures of rabbit pulmonary trunk and artery SMCs were prepared as 
described previously in Section 4.3.1 and 4.3.2.  
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 5.3.1.2  Measurement of PGE2 and 6-keto-PGF1α release 
Confluent PTSMCs and PASMCs cultured on 6-well plates were washed twice with 
phosphate-buffed saline (PBS) and incubated in 1 ml of serum-free medium 
containing 0.1% BSA in a 37oC humidified incubator with an atmosphere of 95% 
air and 5% CO2. After a 30-minute equilibration period, cells were pre-stimulated 
with 100 nM noradrenaline for 5 minutes and stimulated with the angiotensin 
peptide for a further 5 minutes; the timing for addition of noradrenaline and 
angiotensin peptide was to enable correlation with results obtained from isolated 
tissue experiments. After incubation, the medium was aspirated and prostaglandin 
levels in the medium were determined using the prostaglandin E2 and 6-keto-
prostaglandin F1ά (stable metabolite of prostaglandin I2) enzyme immunoassay kits 
from Assay Designs, Inc, MI, USA.  
  
The angiotensin peptides tested include angiotensin II (100 nM), angiotensin III 
(100 nM) and angiotensin IV (10 µM). To investigate the effects of losartan (1 
µM), PD123319 (10 µM) and indomethacin (10 µM) on angiotensin-induced 
prostaglandin release, these compounds were added to the wells at the start of the 
30-minute equilibration period.  
 
5.3.1.3  Expression of results and statistical analysis 
PGE2 and 6-keto-PGF1α content of aspirated culture medium was expressed as % 
basal PGE2 or % basal 6-keto-PGF1α. Basal PGE2 and 6-keto-PGF1α was defined as 
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basal PGE2 and 6-keto-PGF1α release prior to the addition of noradrenaline and 
angiotensin peptide. Control PGE2 and 6-keto-PGF1α were defined as the 
noradrenaline-induced PGE2 and 6-keto-PGF1α release prior to the addition of 
angiotensin peptide. All statistical comparisons were performed using the general 
linear method (univariate) with Tukey’s multiple range test for a posteriori 
comparisons. 
 
5.3.2 Inositol triphosphate studies 
5.3.2.1  Preparation of tissue 
Fresh rabbit pulmonary trunks were removed into ice-cold carbogen-saturated 
Krebs solution as previously described. Connective and adipose tissue were gently 
removed. The vessels were cut open and denuded of endothelium by gently rubbing 
the luminal surface with cotton buds. Cross-chopped pulmonary trunk tissue slices 
(200 x 200 µm) were prepared using a McIlwain tissue chopper. The tissue slices 
were then suspended in 20 ml ice-cold carbogen-saturated Krebs solution per gram 
of tissue and incubated for 1 hour at 37oC in a shaking water bath with replacement 
of carbogen-saturated Krebs solution every 15 minutes. 
 
5.3.2.2  Agonist reaction 
Chopped tissue slices were dispensed as 170-µl aliquots into polypropylene flat-
bottomed vials containing Krebs solution to yield a final volume of 300 µl after 
addition of agonist. The tissue slices were incubated for 15 minutes before the 
addition of agonist. After addition of agonist, the reaction was terminated at 
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selected times by addition of 100 µl of 1.2 M ice-cold perchloric acid. The vials 
were chilled on ice for 15 minutes before the mixture was neutralized with 100 µl 
of 1.2 M freshly prepared potassium bicarbonate. The suspension was centrifuged 
for 10 minutes at 3,000 g at 4oC and the supernatant stored at -20oC for less than 6 
weeks before analysis. 
 
All additions of agonists were made in a volume of 15 µl. The agonists used were 
100 nM angiotensin II and 10 µM angiotensin IV. 
 
5.3.2.3  IP3-binding assay 
The binding assay was carried out using an IP3 kit (D-myo-Inositol 1,4,5-
triphosphate (IP3) [3H]assay system, Amersham Pharmacia Biotech).  
 
Briefly, assays were performed at 4oC in a final volume of 400 µl. 100 µl of assay 
buffer, 100 µl of diluted tracer ([3H]IP3) and 100 µl of IP3 bovine adrenal binding 
protein were added to 100 µl of sample (supernatant) or 100 µl containing a known 
amount of IP3,. The mixtures were vortex mixed, incubated on ice for 15 minutes 
and centrifuged for 10 minutes at 2,000 g at 4oC to separate the bound and free 
[3H]IP3. The supernatant was discarded and the [3H]IP3 bound to the receptor was 
extracted by adding 1 ml of 0.15 M sodium hydroxide, vortex mixing and 
incubating the mixture at room temperature for 10 minutes. The extract was 
neutralized with 50 µl of 10 % acetic acid, vortex mixed, decanted into scintillation 
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5.4.1 Prostaglandin studies 
In noradrenaline-stimulated pulmonary artery smooth muscle cells (PASMCs), 
angiotensin II caused a significant 2.6-fold increase in both PGE2 and PGI2 
(measured as its stable metabolite 6-keto-PGF1α) after 5 minutes (Figure 5.1). In 
similarly treated pulmonary trunk smooth muscle cells (PTSMCs), angiotensin II 
caused a 2.6-fold increase in PGE2 and a 6.1-fold increase in PGI2 above 
noradrenaline-induced PG release (Figure 5.1). These angiotensin II-induced PG 
release was completely inhibited by losartan and indomethacin. In contrast, the AT2 
antagonist, PD123319 did not block the angiotensin II-induced release of 
prostaglandins, suggesting that this effect is mediated only by the AT1 receptor. 
Angiotensin III caused a 2.7-fold increase in PGE2 and a 1.6-fold increase in PGI2 in 
PASMCs, and a 1.8-fold increase in PGE2 and a 1.7-fold increase in PGI2 in 
PTSMCs (Figure 5.2). Smaller increases in PGE2 (1.4-fold) and PGI2 (0.4-fold) in 
PASMCs and in PGE2 (1.7-fold) and PGI2 (1.5-fold) in PTSMCs were also 
observed with angiotensin IV (Figure 5.3). However, both the angiotensin III and 
angiotensin IV-induced increase in prostaglandins were not statistically different 
from control (i.e., noradrenaline-induced PG release), except the angiotensin III-
induced PGE2 release from PASMCs and angiotensin IV-induced PGE2 release 

























































aFigure 5.1 Stimulation of prostaglandin E2 (PGE2) and 6-keto-
prostaglandin F1α (6-keto-PGF1α) production in rabbit pulmonary 
trunk and artery vascular smooth muscle cells by angiotensin II. 
Increases in PGE2 and 6-keto-PGF1α production are given as a 
percentage of the basal PG level and represents the means ± SEM of 
5 independent experiments performed in duplicate. *significantly 





















































Figure 5.2 Stimulation of prostaglandin E2 (PGE2) and 6-keto-
prostaglandin F1α (6-keto-PGF1α) production in rabbit pulmonary 
trunk and artery vascular smooth muscle cells by angiotensin III. 
Increases in PGE2 and 6-keto-PGF1α production are given as a 
percentage of the basal PG level and represents the means ± SEM of 9 
independent experiments performed in duplicate. *significantly 






















































Figure 5.3 Stimulation of prostaglandin E2 (PGE2) and 6-keto-
prostaglandin F1α (6-keto-PGF1α) production in rabbit pulmonary trunk 
and artery vascular smooth muscle cells by angiotensin IV. Increases in 
PGE2 and 6-keto-PGF1α production are given as a percentage of the 
basal PG level and represents the means ± SEM of 6 independent 
experiments performed in duplicate. *significantly different from 
control PG. **significantly different from angiotensin II-induced PG. 
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increase in PGE2 and PGI2 between PTSMCs and PASMCs for all three angiotensin 
peptides tested. 
 
5.4.2 Inositol triphosphate studies 
Rabbit pulmonary trunk tissue slices had an average basal IP3 mass level of 153.5 ± 
39.9 pmol/mg protein. Angiotensin II induced a rapid increase in IP3 (3.3-fold), 
with peak IP3 production within 15 seconds of angiotensin II stimulation, and a 
return to baseline levels thereafter (Figure 5.4). In contrast, angiotensin IV 
stimulated a minimal increase in IP3 (Figure 5.5). 
 
5.5 Discussion 
In order to address two key questions we focused in on the intracellular processes 
responsible for vasoconstriction and vasodilation in VSMCs. Firstly, does the AT1 
receptor mediate distinct and opposite biological responses in the rabbit pulmonary 
trunk and artery due to differences in the receptor-coupled signal transduction 
cascade? Secondly, what is the principle component of the intracellular signaling 
cascade that mediates this action? Although the production of IP3 and 
prostaglandins are well documented events following angiotensin II stimulation, the 
present study profiled and compared for the first time the angiotensin II-, 
angiotensin III- and angiotensin IV-induced prostaglandin and IP3 release from the 































Figure 5.4 Stimulation of inositol triphosphate production in rabbit 
pulmonary trunk tissue by angiotensin II over time. Increases in inositol 
triphosphate production are given in pmoles per mg protein and represents 































 Figure 5.5 Stimulation of inositol triphosphate production in rabbit 
pulmonary trunk tissue by angiotensin IV over time. Increases in inositol 
triphosphate production are given in pmoles per mg protein and represents 
means ± SEM of 3 independent experiments done in duplicate. 
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The results of the present study showed that angiotensin II increased the production 
of two intracellular signaling molecules, PGE2 and PGI2, in the rabbit pulmonary 
trunk and artery. This finding is consistent with previous findings showing that 
angiotensin II stimulates the synthesis of vasodilator prostaglandin in vascular 
tissues and vascular cells in culture, which functions to modulate the vascular effect 
of angiotensin II (Webb, 1982; Wilcox and Lin, 1993). The inhibition of 
angiotensin II-induced prostaglandin production by losartan demonstrates the role 
of the AT1 receptor in mediating prostaglandin synthesis in the rabbit pulmonary 
vasculature, which corresponds to similar findings by other studies (Rao et al., 
1994; Shinoda et al., 1997; Muthalif et al., 1998; Freeman et al., 1998; Silfani and 
Freeman, 2002). Interestingly, the high levels of PG production stimulated by 
angiotensin II in the pulmonary trunk could explain the vasodilation observed in 6 
our of 16 pre-contracted tissue in the isolated tissue experiments (see Figure 2.4, 
page 56). The stimulation of pulmonary trunk and artery VSMCs by angiotensin III 
and angiotensin IV is associated with an increase in both vasodilator prostaglandins 
and a reduction of this release by losartan and indomethacin. However, these 
findings were not statistically significant probably due to the high inter-sample 
variability observed. A possible explanation for the variability observed may be a 
result of phenotypic variations through the continual passage of cells. VSMCs are 
reported to modulate from a physiological ‘contractile state’ to a more ‘synthetic 
state’ when in culture (Chamley-Campbell et al., 1979). High seeding densities and 
a short time to confluency are some of the factors that help to maintain cells in their 
physiological contractile state (McMurray et al., 1991; Birukov et al., 1993). In our 
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experiments, cells from passage 5-12 were used. The variability may be contributed 
by PG release from cells from different passages. Interestingly, the prostaglandin 
levels did not differ between the pulmonary trunk and artery SMCs for all 
angiotensin peptides tested, suggesting that it is unlikely that the opposing 
contractile and relaxant responses observed in the pulmonary artery and trunk were 
a consequence of correspondingly low and high levels of synthesis of vasodilator 
prostaglandins, respectively.  
 
Following this finding, we next investigated if a difference in the IP3 signaling 
component might be responsible for the heterogeneous response of rabbit 
pulmonary trunk and artery to angiotensin peptides. Our present findings 
demonstrate that angiotensin II stimulates a higher production of IP3 in pulmonary 
trunk tissue slices compared to that by angiotensin IV, suggesting that the 
differential angiotensin II-induced vasoconstrictor response and angiotensin IV-
induced vasorelaxant response in the rabbit pulmonary trunk may be due to higher 
amounts of the IP3 second messenger being produced when stimulated by 
angiotensin II compared to angiotensin IV.  
 
The use of different tissue types for the measurement of PGs and IP3, i.e., use of 
cultured SMCs for PG measurement and tissue slices for IP3 measurement, can 
make direct comparisons of IP3 versus PG release in the same tissue difficult. In any 
future experiments, an improved methodology would allow the simultaneous 
measurement of agonist-induced IP3 production and AA release from the same 
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population of cells/tissue. However, it should be noted that the design and findings 
of this study sought to determine if a contractile response was a result of a 
predominance of contractile signaling pathways over relaxant pathways and vice 
versa for relaxant responses. Therefore the findings of this study were adequate to 
address this question even though the assays were performed in different tissue 
systems.  
 
Taken together with the results from the prostaglandin studies, the present findings 
indicate that the response seen in the pulmonary vasculature is likely a result of a 
balance of contractile and relaxant signaling components. In the pulmonary artery, 
angiotensin II and angiotensin III stimulate a higher level of IP3 that predominates 
over the simultaneous production of vasodilator prostaglandin, resulting in an 
overall contractile response. In the pulmonary trunk, because lower levels of IP3 are 
produced, the vasodilator effect of prostaglandins predominates, resulting in 
vasorelaxation. Our present findings suggest that in the rabbit pulmonary trunk, the 
contractile response seen with angiotensin II, in contrast to a relaxant response seen 
with angiotensin IV, was due to a predominant IP3 signaling mechanism that masks 
the vasorelaxing effect of the simultaneous production of vasodilator 
prostaglandins, while angiotensin IV stimulation results in a weak IP3 response 
which is insufficient to overwhelm the modulating effect of vasodilator 




       



















Figure 5.6 Scheme demonstrating mechanisms whereby angiotensin 
II and angiotensin IV stimulation of the AT1 receptor can elicit different 
cellular responses. The resultant response, i.e., contraction or relaxation 
is dependent on the predominance of one signal transduction pathway 
over another. Cross talk can occur between the multiple signal 
transduction pathways activated. 
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Multiple mechanisms of divergence may contribute to the multiple signal 
transduction pathways, i.e., IP3 and PG signaling pathways, stimulated by 
angiotensins in the rabbit pulmonary vasculature. One of the first possibilities we 
considered was the presence of two or more receptor subtypes mediating distinct 
signal transduction pathways possibly via distinct G protein couplings. However, 
both receptor binding and Northern blot analyses suggested that only a single 
receptor subtype mediated these responses. Our isolated tissue and current findings 
also support the notion that a single AT1 receptor was involved, and it is possible 
that this receptor is coupled to a single G protein which, when activated, triggers the 
activation of multiple signaling pathways that contribute to the final vascular 
response. There is increasing evidence to suggest that cross-talk occurs between 
intracellular effectors activated by angiotensin II. For example, angiotensin II 
stimulates the Gαq/11-coupled PLC-dependent hydrolysis of PIP2 to yield IP3 and 
DAG (Griendling et al., 1989). These messengers mediate the intracellular release 
of Ca2+ and activate PKC, respectively. DAG can be converted to AA by the action 
of DAG lipase, which can be metabolized to prostaglandins (Billah, 1993). In 
addition, both Ca2+ and PKC have been implicated in a number of cross-regulation 
of other signaling pathways, including the Ca2+- and CaM kinase II-dependent 
phosphorylation and activation of cytosolic cPLA2 (Muthalif et al., 1998). 
Moreover, the temporal characteristics of each divergent signaling pathway may 
also contribute to the fine-tuning of angiotensin responses. For example, 
angiotensin II has also been shown to activate PLD, which hydrolyzes 
phosphatidylcholine (PC) to choline and phosphatidic acid (Ushio-Fukai et al., 
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1999). Recent studies suggest that the PLD pathway contributes in part to the 
sustained production of prostaglandins via the formation of DAG in VSMCs 
(Gomez-Cambronero et al., 1998) and represents the major pathway by which PKC 
remains activated (Lassegue et al., 1993; Dhalla et al., 1997). The qualitative and 
temporal interaction between multiple signaling pathways may contribute to the 
coordinated angiotensin response seen in the rabbit pulmonary vasculature.  
 
It is also possible that a single AT1 receptor coupled to a single G protein may 
mediate signal divergence via Gα as well as the Gβγ subunit. A critical role of Gβγ 
as a signal transducer for PLC activation was demonstrated by the inhibition of 
angiotensin II-stimulated IP3 formation by electroporation of anti-Gβγ antibody in 
rat VSMCs (Ushio-Fukai et al., 1998). Since it has been suggested that Gβγ-
mediated activation of PLC-β is associated with a relatively low increase in IP3 
(Zhang and Muallem, 1992), it is possible that both Gβγ and Gαq/11 cooperatively 
activate PLC-β to produce large amounts of IP3 in intact VSMCs. Gβγ derived from 
Gα12/13 has also been found to transduce AT1 receptor-mediated tonic PLD 
activation in rat VSMCs (Sasaki et al., 1991).  
 
However, the question still remains of how differential responses are obtained by 
different angiotensin agonists acting on the same AT1 receptor in the pulmonary 
trunk. Angiotensin IV is generally considered a weak agonist of the AT1 receptor, 
thus one general mechanism is through differences in the strength of the stimulus by 
angiotensin II and angiotensin IV. For example, if one second messenger triggers 
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the activation of a second measurable response, the magnitude of the second 
response will be more sensitive to the strength of the original signal (Kenakin, 
1995). Therefore, an angiotensin peptide with a higher efficacy, e.g., angiotensin II, 
may produce measurable effects from both signaling pathways, i.e., IP3 and PG 
production, while the peptide with a lower efficacy, e.g., angiotensin IV, may 
produce measurable effects from the second pathway, i.e., PG production, but 
extremely low amounts of the first, IP3 production. The other mechanism is via the 
recently proposed agonist-directed trafficking of receptor signals (Kenakin, 1995). 
Agonist-directed trafficking is a phenomenon whereby agonists preferentially select 
for one of several receptor conformations, and selectively activate a subset of the 
multiple signal transduction pathways that may be coupled to a single receptor 
subtype. The existence of intermediate or multiple active conformations of GPCRs 
have already been described previously (Gether, 1998, 2000; Kenakin and Onaran, 
2002). It has been shown that the AT1 receptor can attain distinct conformations 
leading to phosphorylation and/or inositol phosphate signaling using angiotensin II 
and Sar1-Ile4-Ile8-angiotensin II, an analog that only activates signaling through the 
constitutive receptors, which underlines the importance of multiple active 
conformations of the AT1 receptor (Thomas, 2000).  
 
Finally, the possibility of a single AT1 receptor coupling to multiple G proteins with 
distinct signaling pathways in the rabbit pulmonary vasculature cannot be ruled out. 
The first evidence for functional coupling of the AT1 receptor with multiple G 
proteins of different classes was demonstrated in 7315c cells (derived from a rat 
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anterior pituitary tumour) expressing angiotensin receptors by Crawford and 
colleagues (1992). The findings from this study indicated that, in addition to the 
AT1-mediated inhibition of adenylate cyclase via the pertussis toxin-sensitive Gi/o 
protein, the AT1 receptor stimulated IP3 production via a G protein that was 
insensitive to pertussis toxin. In a separate study, Ushio-Fukai and collegues also 
showed that the coupling of AT1 receptor in rat VSMCs to both Gαq/11 and Gα12 
proteins was necessary to activate PLC-β (1998). Electroporation of anti-Gαq/11 and 
-Gα12 antibodies significantly inhibited the angiotensin II-induced IP3 production in 
these cells.  
 
The angiotensin IV-stimulated relaxant response mediated by AT1 receptors was an 
unexpected finding, since studies on angiotensin IV have reported either a weak 
contractile response mediated via AT1 receptors (Wright et al., 1996; Champion et 
al., 1998, 1999; Fitzgerald et al., 1999) or a relaxant response mediated via AT4 
receptors in the vasculature (Kramar et al., 1997, 1998; Patel et al., 1998; Coleman 
et al., 1998; Hill-Kapturczak et al., 1999). This is the first report to our knowledge 
of a relaxant response of angiotensin IV mediated by AT1 receptors. Angiotensin II 
is converted to angiotensin IV by the action of APA and APN that sequentially 
cleave two amino acids from the peptide (Reaux et al., 1999a, b). In the pulmonary 
trunk, the vasorelaxant action of angiotensin IV, which is formed when angiotensin 
II is metabolized, may contribute to the modulation of contractile actions mediated 
by angiotensin II. Importantly, this fine-regulation of angiotensin responses in the 
pulmonary trunk, which receives blood directly from the right ventricle, may play a 
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role in the protection of the delicate pulmonary capillaries from excessive systolic 
pressure. Understanding these protective mechanisms may have important 
therapeutic implications in the treatment of pulmonary hypertension. 
 
In conclusion, our present findings demonstrate that AT1 receptors in the rabbit 
pulmonary trunk and artery are coupled to multiple signal transduction pathways. 
Stimulation of the pulmonary trunk and artery with angiotensin II and its immediate 
metabolites, angiotensin III and angiotensin IV, results in a coherent response that 
is a composite of the multiple, often functionally opposing signaling cascades. This 
complex regulation of the rabbit pulmonary vasculature may represent a novel 
mechanism for generating an adequate, highly organized and coherent signal in 
response to environmental factors and suggests that the vessel is not just a passive 






Angiotensins play a fundamental role in controlling the functional and structural 
integrity of the arterial wall and are involved in the physiological processes 
regulating blood pressure and in pathological mechanisms underlying vascular 
disease. The majority of the effects of angiotensins in vascular responses are 
mediated by angiotensin II acting on the AT1 receptor subtype (Touyz and 
Schriffin, 2000). New evidence is emerging that demonstrates, in addition to 
angiotensin II and III, bioactivity of a variety of angiotensin fragments, e.g. des-
Asp-angiotensin I (Sim and Soh, 1995; Sim  and Chai, 1996; Sim and Min, 1998; 
Min et al., 2000), angiotensin IV (Wright et al., 1995) and angiotensin (1-7) 
(Ferrario et al., 1998). In addition, putative binding sites for angiotensin IV (AT4) 
and angiotensin (1-7) have been demonstrated and pharmacologically characterized 
(Wright et al., 1994; Hanesworth et al., 1993; Swanson et al., 1992; Hall et al., 
1993; Bernier et al., 1995; Nuess et al., 1994), although their cloning has not been 
reported. These recent findings have challenged the ‘single’ regulatory peptide and 
receptor concept of the renin angiotensin system and opened up the possibilities of 
poly functional angiotensins in the system.  
 
Angiotensin II elicits complex highly regulated cascades of intracellular signal 
transduction that lead to short term vascular effects, such as contraction, and to 
long-term biological effects, such as cell growth, migration, extracellular matrix 
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deposition, and inflammation. Because of its important role in cardiovascular 
diseases associated with vascular smooth muscle cell contraction and growth such 
as hypertension and atherosclerosis, understanding the mechanisms of actions and 
interactions between angiotensin II and its metabolites is of crucial importance. 
 
Here we provide evidence confirming segment to segment variations previously 
reported in the rabbit pulmonary trunk and artery (Sim and Soh, 1995; Sim and 
Chai, 1996) to angiotensin II and its immediate metabolites, angiotensin III and 
angiotensin IV and propose the cellular mechanisms responsible for this fine 
regulation of pulmonary blood flow from the heart to the lung. Isolated tissue 
experiments show that administration of angiotensin III, angiotensin IV, and in 
some cases angiotensin II, produce opposing responses in the pulmonary trunk and 
artery, respectively, as previously described for the angiotensin peptide, des-Asp-
angiotensin I (Sim and Soh, 1995; Sim and Chai, 1996). The differential response 
between the pulmonary trunk and artery to angiotensin peptides suggests the 
existence of two AT1 receptors. Our findings correlated with a recent report 
showing that angiotensin III produced a pressor followed by a depressor response in 
conscious rabbits (Rowe and Byron, 2000). Different receptor mechanisms were 
initially proposed to mediate the opposing responses since equipressor doses of 
angiotensin II were less effective at producing depressor responses. However, both 
pressor and depressor responses were demonstrated to be mediated by AT1 
receptors since losartan abolished both responses whereas PD 123319 had no effect.  
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Similar opposing contractile and relaxant responses mediated by AT1 receptors 
have also been previously reported (Yoshikazu et al., 1995). Angiotensin II was 
shown to contract canine pulmonary artery and relax the pulmonary vein. Losartan 
abolished both the artery contraction and the vein relaxation whereas indomethacin 
augmented the artery contraction and abolished the vein relaxation, suggesting the 
involvement of AT1 receptors and the production of vasodilator PGs in both 
responses.  
 
To explore the presence of more than one AT1 receptor subtypes in the rabbit 
pulmonary vasculature, we characterised the angiotensin receptors in the rabbit 
pulmonary trunk and artery by receptor binding studies and RNA analysis. Labelled 
125I-Sar1-Ile8-angiotensin II bound to both rabbit pulmonary trunk and artery tissue 
with high affinity and was displaced by Sar1-Ile8-angiotensin II, losartan, 
angiotensin II, angiotensin III, des-Asp-angiotensin I and angiotensin IV but not by 
PD123319 and divalinal-angiotensin IV, suggesting the existence of a single class 
of AT1 receptors in the pulmonary vascular tissue. These data were supported by 
our finding, using Northern blot analysis, of a single AT1 receptor mRNA in both 
pulmonary trunk and artery tissue. Consistent with our results, Burns et al. (1993) 
previously reported the existence of a single AT1 receptor gene in the rabbit.  
 
How then is this differential response mediated? First, are there still unidentified 
receptor subtypes? Second, are the signaling pathways different in the pulmonary 
trunk and artery or are the signaling cascades agonist-dependent? 
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 There remains a possibility that rabbit AT1 receptor subtypes and/or splice variants 
exist but were not detected by Southern (Burns et al., 1993) or Northern blot 
analyses. This may occur if the base sequences between subtypes share a low 
homology such that the receptor probe hybridizes to one but not the other receptor 
subtype, or if they do not differ significantly in length to be visualized as distinct 
bands in a Northern blot. 
 
To elucidate the signaling mechanisms in the rabbit pulmonary trunk and artery, we 
carried out both IP3 and PG measurements. The rationale for investigating these 
signaling molecules was that the PLC-IP3-Ca2+ cascade is the major signaling 
pathway for vascular contraction and vasodilator PGs were implicated in the 
angiotensin-induced relaxation in the rabbit pulmonary trunk as demonstrated by 
the inhibitory effect of indomethacin. Our results demonstrate that angiotensin II 
significantly increased the synthesis of vasodilator PGE2 and PGI2 in the rabbit 
pulmonary trunk and artery, with angiotensin III and angiotensin IV showing a 
similar trend in increasing PG synthesis. This supports previous findings by Wilcox 
and Lin (1993) of angiotensin-stimulated prostaglandin synthesis in the vasculature 
and corroborates the well established role of vasodilator PGs in attenuating 
angiotensin responses (Muthalif et al., 1998). Interestingly, when we compared PG 
levels in angiotensin-stimulated rabbit pulmonary trunk and artery, no significant 
differences were observed. This suggested that it is unlikely that a higher level of 
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PG synthesis in the pulmonary trunk, relative to the artery, accounted for its 
predominantly vasorelaxant response to angiotensins.  
 
Because angiotensin II elicits a similar contractile response in both the rabbit 
pulmonary trunk and artery, we next compared the IP3 signaling profile mediated by 
angiotensin II and angiotensin IV in the pulmonary trunk. We found that 
angiotensin II stimulates a higher production of IP3 in pulmonary trunk tissue slices 
compared to that by angiotensin IV. Taken together, these results suggest that when 
AT1 receptors are stimulated in the rabbit pulmonary vasculature, IP3 and PG 
signaling cascades are activated. The resultant vascular response is a balance of 
contractile and relaxant signaling components which are regulated by synergistic 
interactions and cross-talk between these signaling pathways.   
 
Traditionally, signal transduction pathways are conceptualized in a linear fashion, 
i.e., one receptor subtype coupling to one G protein that activates one effector. 
However, recent evidence has accumulated that demonstrate that the same AT1 
receptor can be coupled to different G protein and/or signaling cascades in the same 
tissue, either simultaneously or in a sequential manner, to elicit multiple 
intracellular signals (Crawford et al., 1991; Ushio-Fukai et al., 1998; Permentier et 
al., 2001). For example, Ushio-Fukai et al. (1998) has previously reported that the 
dual coupling of AT1 receptors in rat VSMCs to both Gαq/11 and Gα12 proteins was 
necessary for angiotensin II-induced PLC-β1 activation. In addition, the angiotensin 
II-induced IP3 production was mediated by the sequential activation of PLC-β1 and 
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PLC-γ, suggesting a novel mechanism for a temporally controlled, highly organized 
and convergent angiotensin-signaling network in VSMCs. Angiotensin II was also 
reported to sequentially activate cPLA2 and PLD via AT1 receptors in rabbit 
VSMCs (Permentier et al., 2001). In this study, the angiotensin II-induced PLD 
activation was shown to be mediated by arachidonic acid metabolites generated 
from the initial stimulation of cPLA2. Thus it is becoming clear that AT1 receptors 
couple to multiple G proteins and/or signaling cascades, as has been reported with 
other G protein-coupled receptors (Hermans, 2003). These synergistic interactions 
between multiple G protein signaling pathways may have an important role in fine-
tuning vascular angiotensin responses.  
 
In addition, recent studies using constitutively activated mutant AT1 receptors 
provide evidence for agonist-dependent conformational selection of the AT1 
receptor (Thomas et al., 2000; Hunyady et al., 2003), which has also been reported 
in other GPCRs (Strange, 1999). Constitutive activation of the AT1 receptor by 
mutations of Asn111 in the third transmembrane helix, the interacting residue for 
Tyr4 of angiotensin II, suggests that the AT1 receptor is maintained in an inactive 
conformation by stabilizing intramolecular interactions which are released upon 
agonist binding (Noda et al., 1996; Balmforth et al., 1997; Groblewski et al., 1997). 
It was proposed that the activation of the AT1 receptor may involve the initial 
disruption of Asn111-dependent stabilizing interactions by Arg2 of angiotensin II, 
which subsequently allows the receptor to be fully activated. This may account for 
the lack of potency of angiotensin IV for the wild-type AT1 receptor since it does 
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not contain the Arg2 residue. Supporting this hypothesis was the increased affinity 
of angiotensin IV for these constitutively active AT1 receptors (Le et al., 2002). 
Importantly, agonist-dependent conformational selection of the vascular AT1 
receptor influences our understanding of the role of bioactive angiotensin fragments 
in regulating vascular responses to angiotensins. 
 
Tissue heterogeneity may also contribute to regional differences in vascular 
response to angiotensins. Different cell population within media smooth muscle 
layer in cell wall exist (Archer, 1996; Frid et al., 1997) which may possess different 
sets of signaling proteins that contribute to the heterogeneous responses when the 
AT1 receptor is stimulated in different cells or segments of the pulmonary 
vasculature. The metabolic pathways of angiotensin peptides may also serve as a 
further fine-tuning tool. Angiotensin II may be broken down to an angiotensin 
peptide that has a lower efficacy in vasoconstriction or may act on its own receptor 
to oppose the original angiotensin II response. Finally the roles of AT1 receptor 
splice variants in providing a further level of fine control of angiotensin responses 
remain to be established. 
 
Altogether, these processes provide cells with a diverse repertoire of mechanisms 
for fine-tuning angiotensin responses that are appropriately adaptive to specific 
environmental signals. Recent evidence suggests that the renin-angiotensin system 
may play a role in contributing to the pathogenesis of pulmonary hypertension, 
since irbesartan, an AT1 receptor antagonist, was shown to prevent lung structural 
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remodeling and pulmonary hypertension following myocardial infarct in rats 
(Jasmin et al., 2003). As pulmonary vasoconstriction is a feature of pulmonary 
hypertension, understanding the role of angiotensins in regulating the pulmonary 
circulation may open up novel therapies that target the renin-angiotensin system in 
the management of pulmonary hypertension.  
 
Our present findings urge a re-evaluation of the complexity of angiotensin signaling 
and the role of the RAS in vascular diseases. Only a complete understanding of the 
mechanisms involved in angiotensin receptor activation and intracellular signaling 
pathways will enable targeted therapies to be developed, which can compensate for 
the intrinsic variation in the function of the angiotensin receptor throughout the 
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